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71.     SUMMARY
The mammalian target of rapamycin (mTOR) is a Serine/Threonine kinase involved inmany cellular processes. In the last decades mTOR has been described to assemble intotwo different complexes: mTORC1 and mTORC2.The mTOR complex 1 is constituted, beside the kinase mTOR, by four other proteins(mLST8, PRAS40, DEPTOR and RAPTOR) and senses the micro-environmental levels ofnutrients, amino acids, energy, oxygen and growth factors. This complex regulates proteinand lipid synthesis, autophagy, glucose metabolism, cell proliferation and growth. Itsactivity can strongly and specifically be inhibited by rapamycin which can induceconformational changes in the kinase and affect the integrity of the complex.The other complex containing the kinase TOR, mTORC2, is constituted beside the kinasemTOR by five regulatory binding proteins (mLST8, DEPTOR, SIN1, PROTOR and RICTOR).The presence of these associated proteins and in particular of RICTOR and SIN1 wasshown to be basic for mTORC2 stability and function. The information regarding functionsand activation mechanisms of mTORC2 are still scarce compared to the well-studied andfirstly described mTORC1.In the last years many groups thus have been investigating the role of the mTOR complex 2and they discovered that its activity is influenced by growth factors stimulation. It hasbeen also demonstrated that mTORC2 can regulate the actin cytoskeleton, cell migrationand growth, mainly acting via its major downstream targets AKT, PKCα (Protein KinaseCα) and SGK1 (Serum and Glucocorticoid- regulated Kinase 1). Differently from its brothermTORC1, mTORC2 is sensitive to rapamycin only in some cell types, such as in endothelialcells, but only after prolonged exposure at higher concentrations.The endothelial cells are the principal constituents of the blood vessels and are directlyinvolved in angiogenesis, a morphogenetic event that consists in the creation of new bloodvessels starting from pre-existing ones. This process is particularly important duringdevelopment, when new blood vessel supply growth and functionality of the body tissuesbut, it can also take place in pathological situations such as during inflammation andtumor vascularization.In the angiogenic process, the endothelial cells are induced to proliferate, migrate anddifferentiate in response of external stimuli such as growth factors or hypoxia.  The tumorcells secrete high doses of growth factors such as VEGF (Vascular Endothelial GrowthFactor) and FGF (Fibroblast Growth Factor) that stimulates the abnormal vascular growthwithin the tumor mass.  In many tumor cells, the mTOR pathway was also found
8particularly active; therefore a first approach to block tumor growth was to use drugstargeting the mTOR kinase.Despite the interesting results obtained in terms of decreased angiogenesis within thetumor and consequent inhibition of the tumor growth, it was not clear whether both of thetwo mTOR complexes are involved in angiogenesis and whether endothelial mTORC2plays a role in this process.In order to understand whether mTORC2 is involved in angiogenesis we used a mousemodel in which the Rictor gene was disrupted in the endothelium as consequence of CRE-mediated genome recombination.During these in vivo experiments we could show that the constitutive ablation ofendothelial Rictor is generally lethal during midgestation (embryonic day 11.5-12.5) andthe few surviving embryos displayed vascular defects and a delayed ossification in fingers,toes and vertebrae.Therefore, to assess the role of mTORC2 in angiogenesis, we decided to induce theknockout in adult animals via Tamoxifen injection.In these mice, we monitored the alteration of the skin muscle capillary architecturestimulated by the FGF2-rich matrigel, on a daily basis using intravital microscopy.Furthermore, we assessed de novo angiogenesis into FGF2-loaded matrigel plugsimplanted under the mouse skin.Our in vivo data clearly demonstrated that the absence of mTORC2 in endothelial cellsleads to a limited FGF2-induced angiogenic remodeling of the capillary vasculature bypreventing the heterogeneous increase of the capillary diameter. Furthermore, Rictorknockout strongly reduced the formation of aberrant capillaries into matrigel plugs. Thus,our data suggested a crucial function of endothelial mTORC2/RICTOR in extensiveangiogenesis.In the wake of these findings, I proceeded to analyze cellular and molecular mechanisms toexplain the phenotypes observed in vivo. To achieve this goal, it was used an in vitrosystem constituted by aortic endothelial cells derived from of mice (MAECs) with a floxed
Rictor gene.Within these cells, mTORC2 functionality was disrupted as consequence of Rictor exonsexcision induced by CRE-recombinase produced in the MAECs after adenoviraltransfection.To mimic an angiogenic environment, the endothelial cells were activated using the twomost important pro-angiogenic molecules FGF2 and VEGFA.From a cellular point of view, I could demonstrate that mTORC2 was not involved in FGF2-induced MAECs proliferation, migration and cytoskeleton rearrangement. However, weclearly observed that FGF2-driven endothelial network formation required RICTOR.
9On the other hand, we observed that VEGFA-induced MAECs proliferation involvedmTORC2 signaling, while VEGFA didn’t act via mTORC2 to induce MAEC-networkformation and -cytoskeleton rearrangement.On a molecular level, I could demonstrate that in primary MAECs, phosphorylation ofPKCα on Ser 657 residue was increased in response to FGF2 and absent after Rictorknockout. Interestingly, the levels of PKCα total protein were strongly dependent onmTORC2 function, whereas PKCα transcription was not affected by Rictor knockout.AKT levels were not affected by mTORC2 ablation, but its phosphorylation on the residueSer473 in response to FGF2 required mTORC2.I could furthermore observe that in quiescent wild-type endothelial monolayers RICTORprotein levels were very low. After FGF2 stimulation, however, intracellular RICTORprotein levels increased in a dose-dependent manner in control cells.Moreover, either under VEGFA or FGF2 stimulation, the presence of mTORC2 did notinfluence the transcription of some of the most important growth factors receptors(VEGFRs) involved in sprouting angiogenesis and endothelial cells differentiation.To obtain then, information on a large scale about mTORC2-regulated genes and proteinsin response to FGF2 and VEGFA, I compared the transcriptome and the secretome of Rictorknockout versus control MAECs. From the comparisons I could not substantiate theexistence of any gene cluster or secreted protein involved in angiogenesis that mightsupport with a molecular explanation the phenotypes observed in vivo. However, I couldobserve that in MAECs, the absence of mTORC2 can regulate the production of growthfactors involved in angiogenesis: indeed, in response to VEGFA, Rictor ablation decreasesthe secretion of HGF, a growth factor which was shown to increase endothelial cellsgrowth and motility and to be particularly expressed in some types of tumors, such asbreast cancer.Furthermore, I saw that, in starved cells, the loss of Rictor increased the transcription of
Ang2, a gene involved in vascular remodeling that can either lead to capillary maturationor, in absence of pro-angiogenic stimuli, even to vessel regression.Interestingly, I could register that the transcription of the pro-inflammatory molecule
Mcp-1 remained at higher levels in MAECs lacking Rictor in response to FGF2, indicating apossible mild inflammatory phenotype in mTORC2 deficient endothelial cells.Finally, I also observed that MAECs produced nitrites in an mTORC2-dependent manner inresponse to acetylcholine, suggesting a possible role of mTORC2 in vasodilation.
In conclusion, based on our results, we can state that endothelial mTORC2 is crucial forembryonic development and its absence leads to lethality, distinct vascular defects,growth retardation and delayed ossification. Moreover, we showed that in adult mice
10
mTORC2 is involved in FGF2-driven angiogenesis: under FGF2 stimulation, mTORC2absence impairs the heterogeneous increase of the capillary diameter in dorsal skin foldmuscle and compromises the formation of aberrant capillaries in matrigel plugs.Mechanistically, these in vivo and in vitro phenotypes might be explained with a reducedactivity of AKT whose phosphorylation on the residue Ser 473 was strongly decreased in
Rictor knockout cells. Another mechanism that may explain the importance of mTORC2 inangiogenesis might be supply by PKCα whose presence was shown to be stronglydependent on mTORC2 integrity.These findings can have an important clinic impact, since we could demonstrate thatmTORC2 is involved in angiogenesis. New therapies targeting specifically this multimericcomplex can be designed in order to prevent aberrant angiogenesis in tumors or in otherdiseases displaying an abnormal vascular growth.
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2.     ZUSAMMENFASSUNG
Die Serin/Threonin-Kinase Mammalian Target of Rapamycin (mTOR) ist an vielenzellulären Prozessen beteiligt. In den letzten Jahrzehnten ist mTOR, in zwei verschiedenenKomplexen, mTORC1 und mTORC2, gezeigt worden.Der mTOR-Komplex 1 besteht neben der Kinase mTOR aus vier weiteren Proteinen(mLST8, PRAS40, DEPTOR und RAPTOR) und erfasst die Mikro-Umwelt Mengen anNährstoffen, Aminosäuren, Energie, Sauerstoff und Wachstumsfaktoren. Dieser Komplexreguliert Protein- und Lipidsynthese, Autophagie, Glukosestoffwechsel, Zellproliferationund das Wachstum. Seine Aktivität wird stark und spezifisch von Rapamycin gehemmt,welches Konformationsänderungen in der Kinase induziert.Der zweite Komplex mTORC2, besteht, neben der Kinase-TOR, aus fünf weiterenregulatorischen Bindungsproteine: mLST8, DEPTOR, SIN1, PROTOR und RICTOR. DasVorhandensein dieser assoziierten Proteine, insbesondere RICTOR und SIN1, ist essentiellfür mTORC2 Stabilität und Funktion. Die Informationen bezüglich Funktionen undAktivierungsmechanismen von mTORC2 sind verglichen mit dem gut untersuchten undzuerst beschriebenen mTORC1 noch immer gering.In den letzten Jahren haben viele Forschungsgruppen die haben Rolle des mTOR-Komplex2 untersucht: Sie haben gezeigt, dass die Aktivität von mTORC2 durch Wachstumsfaktor-Stimulation beeinflusst wird. Daneben wurde auch gezeigt, dass mTORC2 das Aktin-Zytoskelett, Zellmigration und Wachstum regulieren kann. Dies geschieht vor allem überseine wichtigsten nachgelagerten Moleküle in der Signalkette: AKT, PKCα (Protein KinaseCα) und SGK1 (Serum and Glucocorticoid-regulated Kinase 1). mTORC2 nur in einigenZelltypen wie zum Beispiel in Endothelzellen sensitiv auf Rapamycin und dies auch nurnach längerer Exposition und bei höheren Konzentrationen.Die Endothelzellen sind ein Hauptbestandteile der Blutgefäße und sind direkt in derAngiogenese beteiligt. Angiogenese ist ein morphogenetischer Prozess, bei dem neuenBlutgefäßen aus-bereits existierenden geschaffen werden. Dieser Prozess ist  besonderswichtig bei der Entwicklung, wenn neue Blutgefäßversorgung, Wachstum und Funktionder Körpergewebe gebildet werden. Angiogenese kann auch in pathologischenSituationen, wie bei Entzündungen und Tumorvaskularisierung stattfinden.Im angiogenen Prozess werden die Endothelzellen induziert, um Proliferation, Migrationund Differenzierung in Abhängigkeit von externen Stimuli, wie Wachstumsfaktoren oderHypoxie zu vermitteln.Tumore sezernieren hohe Dosen an Wachstumsfaktoren wie VEGF (Vascular EndothelialGrowth Factor) und FGF (Fibroblast Growth Factor), die das abnormale Gefässwachstum
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innerhalb der Tumormasse stimuliert. In vielen Tumorzellen wurde der mTOR-Signalwegals besonders aktiv gezeigt. Medikamente gegen die mTOR-Kinase zu verwenden ist daherein therapeutischer Ansatz, um das Tumorwachstum zu blockieren.Trotz diesen interessanten Ergebnissen im Sinne von verminderter Angiogenese imTumor und damit einhergehender Hemmung des Tumorwachstums, war es nicht klar, obbeide mTOR-Komplexe an der Angiogenese beteiligt sind, und ob mTORC2 in denEndothelzellen eine Rolle in diesem Prozess spielt. Um zu verstehen, ob mTORC2 an derAngiogenese beteiligt ist, verwendeten wir ein Mausmodell, in dem das Rictor Gen imEndothel als Folge einer Cre-vermittelten Rekombination des Genoms konstitutiv oderdurch Tamoxifen-induziert deletiert wurde.Die konstitutive Ablation von endothelialem Rictor in vivo war in der Regel letal nach derHälfte der Schwangerschaft (embryonale Tage 11.5 bis 12.5) und die wenigenüberlebenden Embryonen zeigten Gefässdefekte und eine verzögerte Verknöcherung inFingern, Zehen und Wirbeln.Bei adulten Mäusen beobachteten wir mit Intravitalmikroskopie die Veränderung derHaut- Muskel- Kapillar-Architektur, welche durch FGF2-angereichertes Matrigel stimuliertwurde. Ferner beurteilten wir die de novo Angiogenese in FGF2- beladenen Matrigel Plugs,die unter der Haut von Mäusen implantiert wurden. Unsere in vivo-Daten zeigten deutlich,dass die Abwesenheit von Rictor im Endothel zu einer stark begrenzten FGF2-induziertenAngiogenese führt und das extensive Remodeling von Kapillaren verhindert wurde indemdie Kapillardurchmesser-Vergrösserung begrenzt wurde. Außerdem zeigen endotheliale
Rictor knockout Tiere keine aberrante Kapillarneubildung im Matrigel Plug im Vergleichzu Kontrollen. Wir demonstrieren also eine entscheidende Funktion vonmTORC2/RICTOR in extensiver Angiogenese hin.Basierend auf diesen Ergebnissen habe ich zelluläre und molekulare Mechanismenanalysiert, um den in vivo beobachteten Phänotyp auf molekulare Ebene zu erklären.Hierzu wurde ein in-vitro-System bestehend aus murinen Endothelzellen (mouse aorticendothelial cells, MAECs) verwendet, die aus Mausaorten mit einem gefloxten Rictor Genisoliert wurden. In diesen Zellen wurde die mTORC2 Funktion als Folge von Rictor ExonExzision mittels der CRE-Rekombinase nach adenoviraler Transfektion eliminiert. Um einangiogenes Umfeld in vitro zu imitieren, wurden die Endothelzellen mit den beidenwichtigsten pro-angiogenen Molekülen FGF2 und VEGFA stimuliert.Auf der zellulären Ebene konnte ich zeigen, dass FGF2 getriebene endothelialeNetzwerkbildung RICTOR-abhängig ist. An FGF2-induzierter MAEC Proliferation, -Migration oder Zytoskelett Reorganisation war mTORC2 nicht beteiligt. Weiterhinbeobachteten wir, dass VEGFA induzierte MAEC Proliferation mTORC2 abhängig war.
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VEGFA-vermittelte Bildung von kapillarähnliche Netzwerken in vitro wurde jedoch nurleicht durch Rictor knockout vermindert.Auf der molekularen Ebene konnte ich zeigen, dass die FGF2-vermitteltePhosphorylierung von PKCα an der Position Ser 657 nach Rictor knockout eliminiert wurde.Interessanterweise wurde das PKCα Gesamtprotein nach Rictor knockout abgebaut,während PKCα Transkription stabil blieb. Der AKT Proteinspiegel wurden nicht vonmTORC2 Ablation reduziert, jedoch die FGF2 vermittelte Phosphorylierung von AKT ander Position Ser473.Ich konnte weiterhin beobachten, dass der RICTOR Proteinspiegel im nicht-stimuliertenMonolayer von wildtyp Endothelzellen sehr niedrig war. Nach FGF2 Stimulation jedocherhöhte sich der RICTOR Proteinspiegel stark und in einer Dosis-abhängigen Weise inKontrollzellen.mTORC2 hatte keinen Einfluss auf die VEGFA oder FGF2 stimulierte Transkription voneinigen der wichtigsten Wachstumsfaktor-Rezeptoren (VEGFRs), welche in der“sprossenden” Endothelzell Phänotyp-Änderung und Differenzierung beteiligt sind.Um weitreichendere Informationen zu mTORC2-regulierten Gene und Proteine zuerhalten, verglich ich das Transkriptom und das Sekretom von Rictor Knockout versusKontroll-MAECs nach Stimulation mit FGF2 und VEGFA. Aus diesen Vergleichen konnte ichnicht belegen, dass spezifische mTORC2-abhängige Gen-Cluster oder an der Angiogenesebeteiligte sekretierte Protein, welche die in vivo beobachteten Phänotypen erklärenkönnten, offensichtlich sind. Allerdings konnte ich beobachten, dass durch VEGFA-induzierte Sekretion von HGF durch Rictor knockout deutlich gehemmt war. HGF erhöhtEndothelzell-Wachstum und Motilität insbesondere in einigen Tumortypen, so z.B. beiBrustkrebs.Ferner beobachtete ich, dass in nicht stimulierten Zellen Rictor Ablation zu erhöhter Ang2Transkription führt. ANG2 ist im vaskulären Remodelling beteiligt, und führt entweder zurKapillar-Reifung, oder, in Abwesenheit von proangiogener Stimuli, zur Gefäss-Regression.Weitere Resultate deuten auf einen möglicherweise leicht entzündlichen Phänotyp inmTORC2 defizienten Endothelzellen: Die FGF2-induzierte Transkription des pro-inflammatorischen Moleküls MCP-1 blieb auf signifikant höheren Ebenen in Rictorknockout MAECs. Schließlich habe ich auch beobachtet, dass Nitrite in MAECs in einermTORC2- abhängigen Weise in Reaktion auf Acetylcholin hergestellt wurden, was auf einemögliche Rolle von mTORC2 in Vasodilatation hinweist.Zusammenfassend konnten wir zeigen, dass endotheliales mTORC2 entscheidend für dieembryonale Entwicklung ist und seine Abwesenheit zu Letalität, verschiedenenGefäßdefekten, Wachstumsstörungen und zur verzögerten Knochenbildung führt. Wirhaben gezeigt, dass bei erwachsenen Mäusen mTORC2 in FGF2 vermittelter Angiogenese
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beteiligt ist: Nach FGF2 Stimulation limitiert mTORC2 Defizienz die heterogene Erhöhungder Kapillardurchmesser in den Kapillaren der dorsalen Hautfaltenmuskel. mTORC2Defizienz verhindert auch die Bildung von aberranten Kapillaren in Matrigelplugs.Mechanistisch konnten wir diese in vivo und in vitro-Phänotypen mit einer verringertenAktivität von AKT in Sinne von stark reduzierter Phosphorylierung an Position Ser 473 in
Rictor Knockout-Zellen assoziieren. Ein weiterer Mechanismus, der die Bedeutung dermTORC2 in der Angiogenese erklären könnte, sind die Expressionslevel von PKCα, diestark von mTORC2 Integrität abhängig waren.Die Erkenntnis, dass endotheliales mTORC2 an der extensiven Angiogenese zentralbeteiligt ist, könnte für zukünftige klinische Anwendungen wichtig sein. Insbesonderekönnten neue Therapieansätze, die speziell diesen multimeren Komplex ins Visiernehmen, aberrante Angiogenese verhindern. Anwendungsgebiete könnten Tumore oderandere Krankheiten wie diabetische Arthritis oder altersbedingte Makuladegenerationsein, bei welchen ein abnormales Gefässwachstum beteiligt ist.
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3.     INTRODUCTION
3.1. Development of the circulatory systemDuring evolution, animals developed several strategies to provide all the neededsubstances to cells and tissues constituting their organism and, at the same time, toremove metabolic waste and toxic products (e.g. lactate and oxidized molecules)generated1. These functions by creating internal circulatory systems firstly developed intriploblasts1. The blood vascular system is an example of a circulatory systemcharacterized by the presence of vessels and pumping organs that can be found duringevolution already in annellidae1 (Figure 1A). Vertebrata, however, were the first to line upthe blood vessels with an endothelial layer1. The complexity of the blood vascular systemincreased with the development of the heart (cardiovascular system) which in pisces isconstituted by one atrium and one ventricle in series. In warm blooded animals, i.e., avesand mammalia, the cardiovascular system is composed of four distinct chambers thatcontribute in creating a double circulatory system which divides the oxygenated from thedeoxygenated blood1. In these animals, the heart pushes the blood all over the bodythrough sophisticated structures: the blood vessels ( Figure 1B).
Figure 1. Evolution of the circulatory system.Circulatory system in anellidae (A)2 and in vertebrata (B)3.
3.1.1. Blood vesselsIn mammalia, the blood vessels can be divided in three different groups, each of them withdifferent structures and proprieties: arteries, veins and capillaries 4.
A B
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The arteries, for example, transport the blood from the heart to the periphery and areconstituted by a tight layer of mural cells, able to resist to the high blood pressuregenerated by the contraction of the heart 4.The veins, on the other hand, transport the blood from the periphery back to the heart andare characterized by the presence of valves within the vessel lumen to prevent backflow ofblood that is not anymore under direct pressure by the heart 4.The last class of blood vessels is constituted by the capillaries: very small vessels, with adiameter of 5-10 µm, located in the periphery that connect the small arteries to the smallveins, and allow the fluid transfer through the vessel wall and the surroundingenvironment4.The large vessels, corresponding to arteries and veins are characterized by three differentlayers: tunica intima, tunica media, tunica adventitia (or externa)5.The internal layer, tunica intima , is constituted by endothelial cells (EC) which create acontinuous monolayer that prevent blood leakage 5. Surrounding the endothelium, tunica
media, composed by vascular smooth muscle cells (vSMCs), nerve cells and extracellularmatrix (elastin, collagen, proteoglycans), enables the vessel contraction, whereas, thefibroblast and the collagen fibers present in the external layer, tunica adventitia, provide astructural support for the vessel 5 (Figure 2).
Figure 2. Artery6.The artery wall layers: tunica intima, with ECs and connective tissue; tunica media, mostly characterized byvSMCs and the tunica externa or adventitia composed by collagen and elastic fibers.
3.1.1.1. Capillary structureThe small blood vessels, the capillaries, generally are constituted by an endothelial cellmonolayer surrounded by pericytes and basement membrane that help the maintenanceof capillary structure and physiology 7 (Figure 3A).The endothelial cell monolayer must fulfill different functions and therefore has variousmorphologies: it can be continuous, fenestrated or sinusoidal 8, 9.
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The continuous monolayer of endothelial cells is uninterrupted and allows the passage ofsmall molecules (H2O, gasses, ions) or lipids8, 9. The capillaries characterized by acontinuous monolayer are mostly localized in skeletal muscles and in the skin 8, 9.The fenestrated endothelium, instead, is mostly present in the intestines and in the kidneyglomeruli, because it can allow the passage of bigger molecules through endothelium
fenestrae (diameter 60-80 nm) which is required for the kidneys’ filtration and theintestinal uptake8-10.The sinusoidal endothelium presents an interrupted endothelial cell layer, with openingsthat allow even the passage of circulating cells (30-40 µm in diameter) and is locatedmostly in the bone marrow, in the lymph nodes and in the liver 8, 9, 11 (Figure 3B).
Figure 3. Capillary.Simplified capillary composition: the endothelial layer is surrounded by the basal lamina (or vascularbasement membrane, vBM) and pericytes (A)12. Representation of the three types of endothelium: continuous,fenestrated and sinusoidal (B)13.
3.1.1.1.1. Endothelial cells (ECs)Endothelial cells (ECs) represent the bricks constituting the internal blood vessel layer.They are organized in a cobblestone monolayer 14 and show heterogenic characteristicswithin the same organism but even within the same vascular bed 8. From a structural pointof view, for example, in rat blood vessels, the aortic ECs are longer and narrower (55 x 10µm) compared to the pulmonary artery ECs that are broad and short (30 x 14 µm). In thepulmonary vein, ECs are large and round whereas in the inferior vena cava ECs are long,narrow and rectangular15. ECs can show heterogeneity also from a functional point ofview. In the activated endothelium for example, the presence of the pro-inflammatorymolecule E-selectin is restricted to the venular side of the capillaries and to the venules 16.The generation of the endothelial cell-heterogeneity might be due to the localmicroenvironment or to epigenetic regulation which can modulate the gene expressionand therefore the endothelial cell phenotype 17.
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Despite the different characteristics within the organism, endothelial cells play importantroles in several processes. First of all, they constitute a semipermeable layer thatselectively allows the passage of molecules and cells: small molecules, H 2O and gasses candiffuse by passing between the endothelial cells whereas bigger molecules cross the cellsusing caveolae. The immune cells cross the endothelium layer either in a transcellular wayor as consequence of endothelial cell junctions opening 18, 19. These junctions that seal theendothelial cells to each other can be divided in two important groups. The first one isrepresented by the adherens junctions (AJ), which are located in the basal position of theendothelial cells and are characterized by the presence of the VE-Cadherin molecule, anestablished EC marker (expressed also in cytotrophoblasts 20). The second group includedthe tight junctions (TJ) which are located in the apical part of the ECs and are mostlyconstituted by the proteins claudin, occludin and JAM 21, 22 (Figure 4). The opening of thejunctional complexes is mediated by the cytoskeleton for example in presence of cytokines(e.g. vascular endothelial growth factor, VEGF22, 23) or inflammatory molecules (e.g.interleukins19 or tumor necrosis factor α24).
Figure 4. Endothelial junctions.Tight and adherens junctions connect adjacent endothelial cells contributing to the creation of asemipermeable cellular layer.
Endothelial cells are also an important orchestrator of angiogenesis: they sense thepresence of pro-angiogenic molecules (growth factors, nitric oxide, cytokines, chemokines,hormones) or oxygen and initiate the angiogenic process 25. In presence of pro-angiogenicfactors, the endothelial cells initiate the degradation of the basal membrane and get rid ofthe mural cells in order to be free to migrate, proliferate and establish a network withother endothelial cells25.
Dejana et al. Developmental Cell, 2009
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The inflammation process also requires the activation of endothelial cells 19, 22. In presenceof pro-inflammatory molecules, the endothelial cells, in post-capillary venules, startexpressing E-selectin and P-selectin which facilitate rolling of leukocytes on theendothelium19. Consecutively, the adhesion molecules intercellular adhesion molecule-1(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) are expressed, facilitatingimmune cells to adhere to the endothelium 19. The leukocytes extravasation process is alsomediate by CD31 (or PECAM1), a transmembrane protein that can  associate to theendothelial junctions, considered a marker for ECs (also expressed in leukocytes andplatelets)26.Endothelial cells can also regulate the coagulation process and try to maintain an anti-thrombotic surface27. However, in presence of cytokines, such as interleukins (e.g. IL-6, IL-8) or tumor necrosis factor α (TNFα),  ECs up-regulate tissue factor (TF) expression , thatcan lead to the formation of thrombi28 in pathological situations.
3.1.1.1.2. Mural cells: vascular smooth muscle cells (vSMCs) and pericytesThe vascular smooth muscle cells (vSMCs) are components of the bigger vessels (arteriesand veins) wall29 and characterized, for example, by the expression of the molecularmarker SM22α30. These cells are involved in maintaining the vessel shape and integrity. Inresponse to vasoactive stimuli (e.g. nitric oxide), vSMCs induce vessel contraction andrelaxation leading to alteration of the luminal diameter with consequent modulation of theblood pressure31. It was also observed that vSMCs can also contribute to vessel remodelingduring pregnancy, exercise and after vascular injury 32. When an injury occurs or duringdevelopment, the smooth muscle cells, beside proliferate and migrate, synthesizeextracellular matrix proteins. SMCs also show heterogeneity 33 within the same vessel: theycan be contractile with elongated and spindled shapes or synthetic with an epithelioidphenotype which are characterized by either a cobblestone morphology or rhomboidshapes with higher proliferative and migratory capacity 34. Pericytes are other mural cellssurrounding the endothelium in venules and capillaries 29 and characterized, for example,by the marker neuron glial 2 (NG2). Pericytes are embedded in the basement membraneand are involved in the angiogenic process 35 interacting with the endothelium viaparacrine signaling or by direct physical contact 36. They can regulate endothelial cell-proliferation37, -differentiation and growth arrest 35. The loss of pericytes can lead toaneurysm37, suggesting their involvement in maintaining the vascular structure andfunctionality. Pericytes play also a role in regulating the capillary diameter and thereforein regulating the blood flow38.
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3.1.1.1.3. Vascular basement membrane (vBM)The vascular basement membrane (vBM) is a layer of specialized extracellular matrix (50– 100 nm) that surrounds the endothelium separating it from the connective tissue andconstituting another barrier to the cell extravasation 39.The vBM is formed by several proteins, most abundant are: type IV collagen, laminin,nidogen/entactin and perlecan40. After the interaction with the cell surface these proteinscan self-assemble in a complex network which confers structural support during the tissuedevelopment39. ECs can regulate extracellular matrix dynamics by controlling the matrixcomponents synthesis, secretion or enzymatic degradation 41. During sproutingangiogenesis, for example, the endothelial cells secrete matrix metalloproteases (MMPs)which degrade the vascular membrane allowing the endothelial cell migration withconsequent capillary formation 42. The vBM can also guide endothelial cellsdifferentiation43, migration44 and proliferation45.Endothelial cells can interact with the matrix proteins for example via integrins 46, whichconnect the extracellular environment to the cytoskeleton 47, influence the cell migration48,proliferation, differentiation and survival.
3.2. Blood vessel formationIn vertebrata, the blood vessels are generated in two different ways: vasculogenesis orangiogenesis. In both of the processes ECs, EC precursors and growth factors play a basicrole49.
3.2.1. VasculogenesisThe process of blood vessel generation occurring by a de novo production of endothelialcells is called vasculogenesis49. During this process, which was well described in Danio
rerio (Zebrafish)49, the blood vessels are created in tissues where they are not yet present.During Danio rerio embryonic development, mesoderm-derived endothelial cellprecursors (angioblasts) migrate towards a vascular endothelial growth factor (VEGF)gradient to the embryonic midline. At this location, the assembly of several angioblastsforms the dorsal aorta (DA) and the posterior cardinal vein (PCV) 50-52 (Figure 5).Endothelial cells split into an arterial or a venous phenotype after the assembly of the DAand the PCV, when the DA-associated ECs start expressing their marker EphB2, whereasthe PCV-associated ECs express the marker EphB4 (EphB2 receptor) 53, 54.In adults, vasculogenesis occurs in pathologic situations when circulating endothelial cellsprogenitors (derivatives of stem cells) give rise to new blood vessels after growth factors
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stimulation (e.g. in tumor development 55, in revascularization of ischemic tissues 56 and inendometriosis57).
Figure 5. Vasculogenesis in Danio rerio49.The formation of the DA and PVC occurs within 30 hours after fertilization. The sequence represents thedifferent stages of the two big vessels formation, starting from the angioblasts migration toward the middleline until the hypochord (h). The lumen formation takes place next, first in the DA and then in the PCV.
3.2.2. AngiogenesisAngiogenesis is a process where new blood vessels are generated from pre-existing ones 49.Two different ways of physiological angiogenesis are described in the literature: sproutingangiogenesis58 and intussusceptive angiogenesis (also known as splitting angiogenesis) 59.Angiogenesis takes place mostly during development and was well described in Danio
rerio during the formation of the intersegmental vessels (ISVs) and the dorsal longitudinalanastomotic vessels (DLAV) 50. After the DA and PCV formation, new angiogenic budssprout from the DA and sense chemotactically the vascular endothelial growth factor(VEGF) gradient generated by the somites using filopodia-like structures. These ECsmigrate to the dorsal-lateral surface of the neural tube, branch and then interconnect toform the DLAV50. The new vessels then mature and the blood starts flowing ( Figure 6).In adults, angiogenesis can be induced by inflammation. Leukocytes can be recruited by anactivated endothelium expressing the adhesion molecules ICAM-1 or VCAM-1 8. These cellscan then extravasate by increasing endothelial permeability through the secretion ofVEGF60, 61, a growth factor not only responsible for the endothelial permeability but alsofor the activation of the endothelium. The stimulated ECs can then start proliferating,migrating and remodeling the capillary structure 62, 63.Angiogenesis in adults can be observed also during the ovarian cycle 64, wound healing65 orin pathological situation (such as solid tumor growth 66, rheumatoid arthritis67,atherosclerosis68, cutaneous psoriasis69, eye disease70, 71).
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Figure 6. Sprouting angiogenesis in Danio rerio49.The formation of the intersegmental vessels (ISVs) and of the dorsal longitudinal anastomotic vessel (DLAV)occurs within two days after fertilization. The ISVs are originated from buds sprouting out from the DA. Thefollowing connection between these endothelial cells generates the DLAV.
3.2.2.1. Modulators of angiogenesisIn adults, in physiological situation, endothelial cells are maintained in a quiescent state bya balance of pro-angiogenic and anti-angiogenic molecules. When this equilibrium isbroken and the ECs are stimulated by a higher amount of pro-angiogenic factors occursthe “angiogenic switch” and angiogenesis starts72. The most important growth factors ableto stimulate angiogenesis by enhancing ECs growth, differentiation, migration andproliferation are vascular endothelial growth factor (VEGF) 73 and fibroblast growth factor(FGF)74. However, many other growth factors can have important effects on the bloodvessels and modulate angiogenesis such as platelet derived growth factor (PDGF) 75,hepatocyte growth factor (HGF)76 or transforming growth factor (TGF) 77. Also theconcentration of particular gasses modulates angiogenesis: nitric oxide (NO) 78 and oxygendeprivation (hypoxia)79, 80 were demonstrated to be pro-angiogenic. The thrombospondins(TSPs), on the other hand, are well known anti-angiogenic factors which can counterbalance pro-angiogenic stimulation to maintain the vasculature quiescent 81. Othermolecules, such as the semaphorins can act either as angiogenic inducers or repressors bystimulating respective receptor-mediated intracellular signaling 82.
3.2.2.1.1. Vascular endothelial growth factor (VEGF)Vascular endothelial growth factor (VEGF) is the most studied pro-angiogenic molecule.Historically, it is also known as vascular permeability factor (VPF) because of its ability toincrease endothelial permeability18, 83.This protein is produced and secreted by several cell types (endothelial cells 84, immunecells85, tumor cells86, astrocytes87, neurons88, SMCs89) and stimulates angiogenesis andvasculogenesis73. During angiogenesis, it can induce EC-sprouting 90, -migration62, -proliferation91 and -survival92. VEGF plays also an important role in blood vessel
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maturation during the processes of lumen formation 93 and of establishing the ECpolarity94.VEGF is also involved in inflammation by promoting the expression of V/ICAM-1 and E-Selectin on ECs95, increasing the adhesion of immune cells to the endothelium 96.The most known member of the VEGF family is VEGFA. In endothelial cells, it can beinduced in response to hypoxia via hypoxia inducible factor (HIF) 84 and as consequence ofFGF2 stimulation97.Different VEGFA isoforms can be generated by alternative splicing, which can remove oneor two domains responsible for the interaction with the extracellular matrix (ECM) andlead to a different affinity for the ECM proteins: VEGF 188 (high affinity for the matrix),VEGF164 (middle diffusible) and VEGF120 (lower affinity for the matrix and morediffusible)98, 99.VEGFA has two main membrane receptors: VEGFR1 and VEGFR2. Their expression isrestricted to endothelial cells, with few exceptions (e.g. melanocytes 100, monocytes101,neurons102, hematopoietic cells103, trophoblasts104). In presence of their ligand, thesereceptor tyrosine kinases can homo or hetero- dimerize and lead to auto or trans-phosphorylation causing initiation of intracellular signals that activate the endothelialcells105. Different intracellular pathways can be modulated upon VEGFR2 activation. Themost important are the PI3K/AKT-S6K, which stimulates cell proliferation and survival;the SRC, that regulates cell permeability and survival and the PLCγ1/DAG-IP3/PKC, thatmediates tubulogenesis 105. VEGF treatment of ECs leads also to MAPK pathwayactivation106 and eNOS induction107. Afterwards, the VEGFA-VEGFR2 complex can beinternalized in endosomes and degraded by lysosomes 108.VEGFR1, though having a stronger affinity for VEGFA, mainly acts as negative modulator ofVEGFA effects due to its weak kinase activity and its intracellular signaling remains poorlyunderstood105.As consequence of alternative splicing, VEGFR1 and VEGFR2 can also be lacking of thetransmembrane domains (sVEGFR1 and sVEGFR2). These molecules are secreted in theperivascular space and act as VEGFA scavengers preventing VEGF binding to themembrane receptors109. The presence of these soluble forms in the matrix leads to aVEGFA gradient that helps directed endothelial sprout growth, but also mediates vesselmaturation via mural cells recruitment 109Other members of the VEGF family are VEGFB and PlGF (Placental Growth Factor). Theybind the VEGFR1 and, while the first is involved in embryonic angiogenesis and in heart ECfatty acid uptake, the second one plays an important role during development, ischemia,skin wound healing, inflammation and in tumors 110.
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VEGFC and VEGFD are the other two members of the VEGF family which are mainlyinvolved in lymphangiogenesis and in the development of the lymphatic tissue. Differentlyfrom the other VEGF forms, they can bind, beside VEGFR2, the VEGFR3, strongly expressedon the lymphatic endothelial cells111 (Figure 7).
Figure 7. VEGF forms and their receptors 112.
3.2.2.1.2. Fibroblast growth factor (FGF)The FGF family of growth factors is constituted by at least 20 different proteins which canstimulate angiogenesis and endothelial cell assembly during vasculogenesis 113. Basicfibroblast growth factor (bFGF or FGF2) was the first pro-angiogenic molecule to beidentified74 and it is considered a more potent angiogenic molecule then VEGF 114. FGF2and acid fibroblast growth factor (aFGF or FGF1) can stimulate endothelial cellproliferation115, migration116 and capillary-like network formation 117.The secretion mechanism of FGF1 and FGF2 is still unclear but it is postulated to beindependent from the endoplasmic reticulum-Golgi pathway 118.FGF has a high affinity for heparan sulfates proteoglycans (HSPGs) and can therefore bestored in the vascular basement membrane 119. HSPGs and heparin can help thedimerization of the FGFRs after FGF binding and influence FGF effects 120.There are 4 different FGF receptors on the endothelial cell membrane called: FGFR1,FGFR2, FGFR3, and FGFR4. More variants of FGFRs can furthermore be generated throughalternative splicing121. The kinase activity of FGFRs can lead to auto-phosphorylation ofdifferent tyrosine residues. For example, phosphorylation on Tyr 463 residue induces ECproliferation via mitogen- activated protein kinases (MAPK) cascade 115 whereas Tyr766
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phosphorylation stimulates EC cytoskeletal rearrangement and cellular shape change viaphospholipase C γ (PLC-γ) 122 (Figure 8).It was demonstrated that FGF and VEGF can crosstalk to enhance the angiogenic activity:FGF2 up-regulates VEGF expression in ECs 97, stimulates hypoxia-induced VEGF release viaphosphoinositide 3-kinase (PI3K) or hypoxia-inducible factor 1 (HIF1) 123 and increasesVEGF uptake by up-regulating the Nrp-1 expression in vSMCs 124. In rat embryos, it wasalso observed that VEGF driven vessel assembly was compromised if FGF2 wasscavenged125.
Figure 8. FGF and its receptor 121.The bound of FGF to its receptor leads to the phosphorylation of several residues in the cytoplasmic domainsof the receptors with the consequent activation of different pathways.
3.2.2.1.3. Hepatocyte growth factor (HGF)The hepatocyte growth factor (HGF), also known as scatter factor (SF), is a proteinsecreted by mesenchymal 126 and vascular127, 128 cells that can influence the behavior ofendothelial, epithelial and hematopoietic progenitor cells. This protein modulatesmorphogenesis, cell growth76, cell migration76 and cell proliferation129 and therefore isconsidered a potent pro-angiogenic factor 76. In embryos, it has importance for organdevelopment130, particularly in myogenesis 131; whereas in adults it is involved in tissueregeneration and wound healing132. In pathological situation, HGF can stimulate tumorgrowth. In breast cancer, for example, HGF promotes capillary-like tubes formation 133. Itsreceptor, HGFR (c-Met), is a membrane tyrosine kinase 134, which can activate MAPKcascade to induce endothelial cell migration and growth 135. The anti-apoptotic effect ofHGF is mediated in EC through bcl-2 up-regulation 136, whereas EC proliferation can bestimulated by the activation of the PI3K-AKT pathway 137. The PI3K-AKT pathway activated
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in EC after HGF treatment leads also to cytoskeleton rearrangement, lamellipodiaformation and consequent migration induction 138.
3.2.2.1.4. HypoxiaThe presence of oxygen (O2) within tissues is basic for metabolic cellular activities. Thecorrect oxygen supply is provided by erythrocytes which carry hemoglobin-bound oxygenfrom the lungs throughout the body using blood vessels as transport path 139. A hypoxiccondition is generated when a tissue doesn’t receive the correct amount of oxygen. In thisstatus, vascular remodeling and angiogenesis are induced such as it happens duringdevelopment (e.g. in retina vasculartization 80, 140), wound healing65 and in pathologicalsituations (e.g. in tumors79, atherosclerotic plaques68, retinopathies70, 71 or rheumatoidarthritis67).On a cellular level, hypoxia has been shown to stimulate endothelial cell migration 141 andnetwork formation142, whereas contradictory data are published about hypoxia-driven ECproliferation141, 143.Hypoxia induces angiogenesis generally by up-regulating VEGF 84. Endothelial cells cansense the presence of oxygen by molecules called hypoxia inducible factors (HIFs) 144whose family is constituted by several members. The most studied components of thisfamily are the αβ heterodimeric proteins HIF-1 and HIF-2. The subunit HIF-1β (also namedARNT) is constitutively expressed and can bind HIFα in hypoxic conditions. In normoxia,the HIF functionality is primarily regulated by prolyl hydroxylases (PHDs) which promotethe binding of the von Hippel-Lindau protein (VHL) to HIFα with consequentubiquitination and proteolytic degradation of the subunit 145 (Figure 9).
Figure 9. Hypoxia leads to VEGF expression via HIF system 146.In normoxia, due to the VHL protein mediation, HIFα is degraded by the proteasome. In oxygen absence, VHLprotein doesn’t mediate the HIFα degradation and the HIF complex is formed leading to gene transcription.One of the genes induced by the activation of the HIF system is VEGF which leads ECs proliferation withconsequent tissue vascularization.
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The erythropoietin (EPO) gene, one of the first genes identified to be up-regulated inhypoxic condition, is transcribed by the stabilized HIF complex 147. Several other genesinvolved in angiogenesis can also be modulated in endothelial cells in hypoxic conditions:
Vegf84, Ang2148, Pdgf-b149, Mmp2150, Vegfr1-2151, soluble Vegfr1152, inducible Nitric oxide
synthase (iNOS) 153.On the post transcriptional level, hypoxia was shown to regulate VEGFR2 154 activity andstabilize Vegf mRNA translation in 293T cells155, enhancing its pro-angiogenic effects.
3.2.2.1.5. Nitric oxide (NO)Nitric oxide (NO), or nitrogen monoxide, is a reactive inorganic gas with an unpairedelectron that confers it free radical properties. It has biological half-life of few seconds andit is rapidly oxidized to nitrites (NO 2−) and nitrates (NO3−) in blood and tissues (Figure
10). The amount of nitrites can be assessed by colorimetric Griess reaction 156.Many cell types, such as endothelial cells157, macrophages158, monocytes159, neutrophils160and neurons161 can synthesize NO, in presence of calmodulin,  from the substrates: L-arginine, O2 and nicotinamide adenine dinucleotide phosphate (NADPH) by using the nitricoxide synthase (NOS) enzymes 162, 163.
L-arginine + ଷ
ଶ
 NADPH + H+ + 2 O2⇄ citrulline + NO + ଷଶ NADP+
Mammals possess three different NOS types: neuronal (nNOS or NOS1), inducible (iNOS orNOS2) and endothelial (eNOS or NOS3). The nNOS, particularly expressed in neurons 161and type II skeletal muscles 164, is mostly involved in cell communication 165 whereas iNOS,present in immune cells158-160, and induced by cytokines, contributes to the responseagainst pathogens166, 167. Differently from the other two NOSs, eNOS is a membrane-associated protein present in endothelial cells168, whose activation, with consequent NOproduction, leads to SMCs relaxation and consequently to vasodilation 169, 170. It wasobserved that also the wound healing process 171 and the VEGF-induced endothelialpermeability78 are facilitated by eNOS.Nitric oxide can be considered a pro-angiogenic molecule for several reasons, for example,on the cellular level it can stimulate EC migration 172, proliferation171, 173 and survival174, 175.Molecularly, nitric oxide and eNOS are involved in angiogenesis on two different stages:either they mediate the effect of angiogenic factors or they stimulate the expression ofthese molecules.In endothelial cells, NO mediates VEGF mitogenic effects 176 and, at the same time, itsproduction via eNOS is stimulated by VEGF 107. In literature, however, in parallel to the
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works on endothelial cells presenting VEGFA as a molecule that up-regulates eNOS mRNAor eNOS activity107, 177 there are some studies demonstrating that VEGFA has no effects oneNOS regulation178 (Figure 10).Despite that, the idea that NO and eNOS can stimulate angiogenesis is sustained by thestudies showing that FGF2 can up-regulate eNOS and, at the same time, in endothelial cells,NO can induce FGF2 expression 173.The effect of hypoxia, a condition that, as shown before, leads to angiogenesis, on eNOS isalso still not clear: while hypoxia is reported to be an eNOS transcriptional repressor179, 180,there are some other publications demonstrate the opposite effect 181.NO can fulfill its pro-angiogenic effects not only on endothelial cells but also on vSMCs,where it is shown to induce a strong VEGF expression 182.Despite the physiological activity of NO, this molecule can be involved in different vascularpathologies: an impaired NO production is a characteristic of diseases such asatherosclerosis183 or hypertension184. Nitric oxide has also important anti-inflammatoryproprieties, but when it is overproduced (e.g. in rheumatoid arthritis), it can induceinflammation185. Despite that, the pro-inflammatory cytokine TNFα was shown to beresponsible for eNOS down-regulation in endothelial cells 186, 187, even if it was observedthat TNFα treatment of endocardial ECs increased nitrite levels 188.Another interesting feature of nitric oxide is its anti-thrombogenic propriety, whichinhibits platelet aggregation by increasing their cyclic adenosine monophosphate (cAMP)concentration189.
Figure 10. VEGF induces NO production and angiogenesis via eNOS activation 190.As consequence of VEGF stimulation, nitric oxygen synthase is activated. The nitric oxide produced leads to theactivation of a cascade of intracellular events causing endothelial cell migration, proliferation andangiogenesis. Nitric oxide is unstable and it is rapidly oxidized to nitrites and nitrates.
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3.2.2.1.6. Thrombospondins (TSPs)Thrombospondins (TSPs) are proteins mostly secreted by platelets 191 or endothelialcells192 leading to several anti-angiogenic effects 81. The most studied member of this familyis TSP1. TSP1 inhibits EC proliferation 193 and growth194. By binding the CD36 antigen onthe EC membrane195, 196, TSPs can also impair EC migration 194 and apoptosis197 .On a molecular level, it is shown that TSP1 can inhibit tumor angiogenesis by blockingVEGF release from the vBM and by inhibiting the activation of the matrix metalloprotease9 (MMP9)198. Moreover, the TSPs can fulfill their anti-angiogenic action by scavengingVEGF199, FGF200 and HGF201 or, even inhibiting NO signaling after binding to the cellularantigen CD47202.Due to all these anti-angiogenic proprieties, therapies administering exogenous TSPs orproteins stimulating TSPs secretion are considered or used in the first clinical trials inorder to block tumor vascularization and growth 203, 204.
3.2.2.2. Sprouting angiogenesisSprouting angiogenesis is a specific form of angiogenesis that is composed of severalstages regulated by growth factors and coordinated by an intense intra and inter-cellularsignaling. These molecules initiate a cascade of processes that lead to: activation of theECs, local degradation of the basal membrane (vBM) by matrix metalloproteases (MMPs),loss of pericytes and SMCs, EC migration, proliferation, network formation, lumencreation, recruitment of new pericytes and SMCs, deposition of new vBM molecules andfinally blood flow58.
3.2.2.2.1. Notch system: tip/stalk cell differentiationOne of the basic pathways involved in sprouting angiogenesis is represented by theNotch/Dll4/Jagged signaling pathway. In angiogenic conditions, small differences in VEGFconcentrations might selectively activate some ECs in the quiescent endothelium 205. Whenthe interaction between VEGF and VEGFR2 activates the EC, the cell acquires anendothelial tip-cell phenotype, which is characterized by an increased mobility and ahigher number of filopodia 90. On a molecular level, the tip cell down-regulatesVEGFR1/sVEGFR1206 and starts expressing more VEGFR2 206, VEGFR3207 and themembrane protein delta like ligand 4 (DLL4) 208.The tip cell communicates to the neighboring ECs by the interaction between DLL4 and itsreceptor Notch present on the ECs. When the Notch pathway is activated, a cascade ofintracellular signals leads to the repression in the ECs of the potential tip phenotype and
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stimulate the differentiation in stalk cells 208. These cells are characterized by a lowermigration but higher proliferation rate and by well-established intercellular junctions 90.Molecularly, the stalk cells display a high Notch signaling which leads to a weakeractivation of the cell, characterized by VEGFR2 down-regulation 209 and VEGFR1/sVEGFR1expression increase210.The stalk cells communicate back to the tip cells via the membrane ligand Jagged1, whichbinds Notch expressed on the tip cells and contributes to inhibit its signaling in tip cells 211(Figure 11). These interactions facilitate the generation of the angiogenic sprouts led by atip cell with high migratory ability, sensing and following the VEGF gradient. The tip of thesprout is followed by proliferating stalk cells responsible for the tube elongation byproliferation and consecutive lumen formation 90. A new capillary is generated when tipcells belonging to different sprouts contact each other: only after, the vessel starts beingperfused by blood. In case of shear stress absence, the sprout regresses 212.
Figure 11. Tip and Stalk cell selection is dependent on the Notch signaling pathway 213.The VEGF gradient drives sprout formation. Within the sprout the cells communicate to each other:  the tipcells that migrate sensing the VEGF gradient are followed by the proliferating stalk cells. The two species ofendothelial cells express different VEGFRs due to the Notch signaling between tip and stalk cells. Tip cellsexpress high levels of VEGFR2 and low amount of VEGFR1 and sVEGFR1. Through DLL4 the tip cell repressesthe VEGFR2 and increases VEGFR1 and sVEGFR1 expression in the following stalk cells.
3.2.2.2.2. Lumen formationTwo models that can explain the vascular lumen formation process during sproutingangiogenesis are cell or cord hollowing. During cell hollowing, pinocytic vesicles, fusing toeach other within the EC, create large and empty vacuoles. Neighboring ECs can merge
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their vacuoles by exocytosis generating an elongated and continuous vacuole along theendothelial sprout. These empty vacuoles fuse then to the lumen of the perfusedcapillary214, 215. Since the vesicles merging in vacuoles carry endothelial surface markers,the polarity of the endothelial cell is established during the lumen formation process 215.However, the most common mechanism explaining the vascular lumen formation is cordhollowing. Cord hollowing process starts from a double EC layer and it requires arepolarization of the ECs 216. The opposing ECs move all the pinocytic vesicles, carrying theapical markers (e.g. CD34 sialomucin) to the interphase where they fuse together to form anarrow lumen within the EC double layer217 (Figure 12). The CD34-sialomucin negativecharges, the cytoskeleton (F-actin fibers and microtubules) rearrangement and the VE-Cadherin redistribution, separates then the apical sides of the two opposing ECs andincreases the luminal diameter216, 217.
Figure 12. Vascular lumen formation models: cell and cord hollowing 218.In hollowing models, the lumen is created by merging the vacuoles of different cells. The main differencebetween the two models is that while in cell hollowing is required a line of endothelial cells, the cord hollowingneed an endothelial cells double layer.
3.2.2.2.3. ANG-TIE2 interaction: vessel maturationIn order to become functional, the sprouting capillary needs to recruit pericytes and to re-establish the vBM. At the site of active angiogenesis, ECs can recruit pericytes by releasingplatelet derived growth factor (PDGF)219. The pericytes sense and move towards the PDGFgradient by the receptor PDGFR and contribute to the capillary stabilization byenwrapping it220. The interaction between endothelial cells and pericytes becomesstronger with the ANG-TIE2 cross-talk. The TIE receptors (TIE1 and TIE2) aretransmembrane proteins with a tyrosine kinase activity 221. TIE2, in particular, isconsidered an EC marker222 because of its characteristic expression in the endothelium,
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although it can also be found on monocytes/macrophages 223 and hematopoietic cells224.Angiopoietin 1 and 2 (ANG1 and ANG2) are multimeric ligands mostly secreted byplatelets225 pericytes226 and endothelial cells227 that compete for the TIE2 receptor228, 229.ANG1 promotes vessel stability and maturation by mediating pericytes interaction withthe ECs230. ANG2, instead, is expressed at the sites of remodeling endothelium anddestabilizes the vessel architecture: ANG2 intravitreal inoculation leads to pericytesloss231. ANG2 expression is highly regulated: in quiescent endothelium it is low, whereas itincreases in hypoxic condition148, 232 and under VEGF148 or tumor necrosis factor α(TNFα)233 stimulation. The presence of VEGF associated to the ANG2 signaling on theendothelium is crucial to decide the future of the remodeling vessel: VEGF and ANG2 co-presence leads to vessel growth, whereas the absence of VEGF during ANG2 stimulationleads to vessel regression by EC apoptosis 234 (Figure 13).
Figure 13. Implication of ANG-TIE2 system in vessel maturation 235.Due to the ANG1 presence, a sprout can mature and stimulate the interaction with the pericytes. On the otherhand, when ANG2 is released, the pericytes detach from the endothelial monolayer and the vessel isdestabilized. In this condition, the presence of VEGF induces angiogenesis, whereas its absence leads to vesselregression.
3.2.2.3. Intussusceptive angiogenesisIntussusceptive angiogenesis is another mechanism of angiogenesis, described for the firsttime during the postnatal growth of rat lung capillaries 236, 237. This type of vessel formationconsists in the splitting of an existing blood vessel in two different ones, due to aprotrusion of the vessel wall into the capillary lumen. The first step of the intussusceptionprocess requires an increase of the existing vessel size followed by the direct contact ofthe endothelial cells present on the opposite side of the capillary wall. After that, theendothelial layer and the basal membrane are cut and a pillar is formed. The final step
33
consists in the pericytes and fibroblasts invasion of the pillar, with consequent matrixformation, and maturation of the new blood vessels 238, 239 (Figure 14). This angiogenicmechanism contributes to expand the vascularized surface. Compared to sproutingangiogenesis this process is much faster and morpho-energetically more efficient since itdoesn’t require endothelial cell migration and proliferation, base membrane degradationand invasion of the surrounding tissue 59, 238, 239.
Figure 14. Intussusceptive angiogenesis 240.A single blood vessel, as consequence of pillar formation is split in two increasing the vascularized area.
3.3. Pathological angiogenesisAngiogenesis is a highly regulated process that takes place mostly during development inphysiological condition. In adulthood, anti-angiogenic molecules counterbalance thesignaling coming from pro-angiogenic ligands and maintain the endothelium in aquiescent state. When this equilibrium is broken angiogenesis restarts 72. However, whenthe presence of pro-angiogenic signals is strong and sustained, an uncontrolledangiogenesis begins, leading to the development of an un-functional, immature andaberrant vasculature that can drive malignancy and pathologies. Two of the majorconditions that unbalance the equilibrium are hypoxia and inflammation. A hypoxicenvironment, as previously described, leads to the induction of VEGF, the most studiedpro-angiogenic factor84, 87. Similarly the immune cells, recruited by the endotheliumthrough pro-adhesive molecules during the inflammation process, secrete VEGF 8. Thisinflammatory reaction increases endothelial permeability 8 and, at the same time, can alsostimulate angiogenesis60, 61. Age related macular degeneration, rheumatoid arthritis andtumor development are three examples of pathologies characterized by aberrantangiogenesis.
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3.3.1. Angiogenesis in wet age-related macular degeneration (wARMD)The retina is a highly organized tissue characterized by the presence of photoreceptors,cells which have an elevated metabolic demand with high oxygen consumption. Withaging, cell waste and immune system-related molecules can accumulate under the retinalpigment epithelium (RPE) and generate small glycolipids and protein deposits called“drusen”241-243. Immune cells, such as macrophages, converge with the drusen and try toeliminate the deposits 244. In this area, the immune cells and a hypoxic environment lead toan increase in VEGF concentration 243, 245. The presence of high amount of VEGF stimulatesaberrant angiogenesis: an uncontrolled growth of the choroidal vasculature through theBruch’s membrane. The invasion of the subretinal space causes the disruption of thephotoreceptor architecture, leading to vision impairment 243. Moreover, in the late stages,the continuous VEGF stimulation contributes in making the new vessels in the subretinalspace extremely permeable and prone to breakage 243. Local hemorrhages are markers ofwARMD which aggravates the pathology of vision loss 243 (Figure 15).
Figure 15. Vascularization in wet ARMD.The photoreceptors layer architecture is disrupted as consequence of the vascularization of an area betweenthe retinal pigment epithelium and the Bruch’s membrane. The vessels generated are weak and prone tobreakage, generating hemorrhages. This situation leads to vision impairment and in the worst cases even toblindness.
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3.3.2. Angiogenesis in rheumatoid arthritis (RA)Rheumatoid arthritis (RA) is a chronic inflammatory disease leading to stiffness inmultiple joints and, in the worst cases, to cartilage and bone damage 246, 247. During RA, thesynovium is infiltrated by a high number of cells involved in inflammation 246 whose levelscorrelates to the increasing levels of VEGF 49 and TNFα248. The high proliferative andmetabolic cellular activity within the synovium creates a hypoxic environment whichboosts VEGF release247, 249, 250. The presence of VEGF activates the endothelial cells thatstart proliferating leading to angiogenesis 247. The induced vascularization of the synoviumcan provide nutrients and oxygen to the active cells in the synovium responsible to thedamages in the joint (Figure 16).
Figure 16. Angiogenesis in rheumatoid arthritis 251.
3.3.3. Angiogenesis in tumorsThe high metabolic activity of tumor cells requires a supply of a large amount of nutrients(e.g. glucose) and other metabolites252. In order to obtain all the needed molecules, thetumor cells stimulate angiogenesis by secreting a large variety of growth factors 66, 253.Moreover, due to the high metabolic activity of the tumor cells a hypoxic environment isgenerated and that additionally stimulates the secretion of VEGF 254. Immune cells, such astumor associated macrophages (TAMs) and TIE2-expressing monocytes (TEMs) arefrequently present in tumors. These cells contribute to angiogenesis and tumor growth bysecreting pro-angiogenic factors such as VEGF and matrix metalloprotease 9 (MMP9) 255,256. The continuous growth factors stimulation leads to aberrant angiogenesis,characterized by the generation of tortuous, dilated, leaky and immature capillaries thatare poorly stabilized by pericytes 257 (Figure 17). These characteristics lead to highinterstitial pressure, hypoperfusion and heterogeneity in blood flow and oxygenationwithin the tumor which remains in large part hypoxic 257. Tumor vascularization, however,can also follow other mechanisms: vasculogenesis induced by circulating EC progenitors,
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vascular co-option and vascular mimicry were observed during solid tumordevelopment258.
Figure 17. Tumor angiogenesis257.Due to extreme and sustained growth factors stimulation, the endothelial cells create an aberrant vasculaturein tumors. The capillaries (in red) are dilated, tortuous and lacking of pericytes growth (in green).
3.3.4. Anti-angiogenic therapiesIn the last decades, several anti-angiogenic therapies were designed in order to rescuepatients from pathologies such as tumors, eye diseases, atherosclerosis, cutaneouspsoriasis and rheumatoid arthritis 259, 260. At the base of these strategies lays the idea thatinhibiting vascular growth or normalizing its characteristics can attenuate the diseasesymptoms or can even contribute to defeat the pathology. Several molecules weredesigned to target specific pro-angiogenic factors, such as VEGF. These molecules can acton the growth factor-pathway at different levels by blocking VEGF/VEGFRs synthesis (e.g.ribozymes)261, 262, scavenging VEGF (e.g. anti-VEGF antibodies263, their fragments264,aptamers265, traps266 or sVEGFR1267), competing for VEGFRs 268 or inhibiting the VEGFRssignaling269 (Figure 18). Some of these molecules are used in clinics since less than 10years, obtaining interesting therapeutic results 263, 264. The use of antiangiogenic drugs is
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very effective in neo vascular ARMD patients: the association of the vetreporfinphotodynamic therapy (PDT) with the intravitreal injection of anti-VEGF antibodyfragment led to a better result in terms of visual acuity in one year 270. In vascularizedcarcinomas, the use of the anti-VEGF antibody can increase the radiotherapy efficacy bynormalizing the tumor vasculature leading to a better tissue oxygenation 257, 271.  However,tumors were shown to be able to develop resistance against anti-VEGF therapies, probablyby inducing other growth factors pathways, such as FGF/FGFR: therefore a synergisticinhibition of both VEGF and FGF signaling pathways might lead to a better and stabletherapeutic strategy272-274. Other methodologies oriented to reduce pathologicalangiogenesis are based on the use of anti-inflammatory agents, such as non-steroidal anti-inflammatory drugs (NSAIDs). The NSAIDs inhibit the pro-inflammatory cyclooxygenase 2(COX2). COX2 leads to prostaglandins production that correlates with VEGF expressionmaking the NSAIDs interesting molecules to indirectly block tumor angiogenesis andgrowth275.
Figure 18. Anti-angiogenic therapies targeting VEGF 276.Several drugs are designed in order to block angiogenesis acting of VEGF. These molecules can act: directlytargeting VEGF (a, b, c), binding VEGF membrane receptors (d, e) or blocking VEGFRs intracellular signaling(f).
3.4. The mammalian target of rapamycin (mTOR)In the 1975, an antifungal metabolite secreted from the bacterium Streptomyces
hygroscopicus was discovered on the island of Rapa Nui 277. This macrolide was namedrapamycin and exhibited strong anti-proliferative proprieties. In 1991, targets of
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rapamycin (TOR1, TOR2 and FKBP12) were characterized in Saccharomyces cerevisiae:mutations in these genes confer rapamycin resistance to yeast 278. In 1994, a TOR ortholog(mTOR) was found in mammals 279, 280. The mammalian TOR is a serine/threonine proteinkinase, downstream to phosphatidylinositol 3-kinase (PI3K), present in two distinctcomplexes called mTORC1 and mTORC2 which are composed by unique and commonproteins and have different functions, targets and sensitivity to rapamycin 281, 282 (Figure
19).
Figure 19. Schematic representation of mTOR signaling pathway 283.
3.4.1. The mammalian target of rapamycin complex 1 (mTORC1)The mammalian target of rapamycin complex 1 (mTORC1) is constituted by the coreprotein kinase mTOR and by four other regulatory binding proteins: mLST8, PRAS40,DEPTOR and RAPTOR281, 284.Rapamycin by binding the intracellular receptor FKBP12 generates a complex that targetsthe FKBP12-Rapamycin Binding (FRB) domain which blocks mTORC1 activity either bychanging the kinase conformation or affecting the complex integrity 279, 281, 285, 286.The mTOR complex 1 senses nutrients and energy levels and its activity is controlled bygrowth factors, amino acids, oxygen and oxidative stress 281, 284, 286, 287.One of the main function of mTORC1 is to control the protein de novo synthesis but it isalso involved in autophagy inhibition 288, 289, control glucose homeostasis control290, 291 andlipid synthesis regulation 292, 293.
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It is activated by the GTP-Rheb protein which is maintained inactive by the tuberoussclerosis complex (TSC1/2) 294, 295. Growth factor stimulation induces the PI3K/Raspathway that leads to AKT and MAPK–dependent TSC2 phosphorylation. When thisphosphorylation occurs, the TSC1/2 complex falls apart and consequently mTORC1 isactivatied295. Cytokines, such as TNFα, instead, activate mTORC1 by phosphorylating TSC1through IKKβ296.When adenosine triphosphate (ATP) concentration decreases, 5' adenosinemonophosphate activated protein kinase (AMPK) can block mTORC1 activity either viaTSC2 or by directly phosphorylating RAPTOR 287, 297. HIF1α, stabilized in hypoxicconditions, induces REDD1 transcription which protects TSC1/2 complex integrity leadingto the consequent mTORC1 hypophosphorylation and inhibition 298.The two major downstream targets of mTORC1 are involved in the protein synthesis: p70ribosomal S6 kinase 1 (S6K1) and the eukaryotic initiation factor 4E (eIF4E) bindingprotein 1 (4EBP1)281, 299.
3.4.1.1. p70 ribosomal S6 kinase 1 (S6K1)S6K1 induces the protein synthesis by activating the ribosomal protein S6 (S6RP) and theeukaryotic translation initiation factor 4B (eIF4B) 299-301.S6K1 function is induced by mTORC1 mostly by phosphorylation on Ser 371 and Thr389,which allows further phosphorylation by PDK1 299, 302, 303.However, through a negative feedback loop, activated S6K1 can also decrease mTORC1activity by inhibiting the sensitivity to insulin of its receptor, inducing insulin resistance indiabetes mellitus304. This negative feedback loop involving mTORC1, GSK3 and IRS isactivated also in cells lacking of mTORC1 inhibitor complex TSC1/2 305, 306.
3.4.1.2. Eukaryotic initiation factor 4E (eIF4E)Active mTOR complex 1 induces the protein synthesis also by phosphorylating thetranslation inhibitor 4EBP1. When this regulation occurs, it provokes 4EBP1 withdrawalfrom the eukaryotic translation initiation factor 4E (eIF4E) which is then free to bindeIF4G and recruit eIF4A and eIF4B. This newly formed complex binds the 5’-CAP of themRNA and start the translation process 299, 307.
3.4.2. The mammalian target of rapamycin complex 2 (mTORC2)The mammalian target of rapamycin complex 2 (mTORC2) is a multimeric complex thatsimilarly to mTORC1, contains the proteins mTOR, mLST8 and DEPTOR, but, differently
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from it, is characterized by the regulatory proteins SIN1, PROTOR and rapamycin-insensitive companion of TOR (RICTOR) 308. RICTOR or SIN1 are critical for mTORC2stability and their ablation leads to the disruption of the complex.Differently from mTORC1, mTORC2 is inhibited by rapamycin only in some cell types (e.g.ECs, vSMCs) and only after long exposure 309. Treatment with rapamycin leads to adecreased mTORC2 signaling, probably due to a diminished availability of the free mTORkinase309.Growth factor stimulation can influence mTORC2 activity 310. Phosphatidylinositol 3, 4, 5 -triphosphate (PIP3), produced by the phosphoinositide 3-kinases (PI3K) is one upstreamregulator of mTORC2311. Recently, it was demonstrated that even TSC1/2 is required formTORC2 activity294.Differently from mTORC1, mTORC2 functions are only beginning to be explored; it ishowever known that mTORC2 specifically can regulate the actin cytoskeleton 308, 312, 313 , thecell growth313 and migration mostly by modulating the activity of its major downstreamtargets: AKT309, PKCα308, 313 and SGK1314.
3.4.2.1. AKTAKT (or protein kinase B, PKB) regulates the activity of a myriad of substrates that areinvolved in many cellular processes, such as proliferation 315, 316, survival92, 316, 317 andmigration62, 316, 318. AKT plays a central role also during angiogenesis since, in endothelialcells, it is activated in response to VEGF 23 and it also mediates VEGF production in hypoxicconditions319.The role of AKT signaling in angiogenesis was studied in physiological situations (e.g.during development) and in pathologies, such as during tumor vascularization 316, 320-323. Inmelanoma, for example, it was shown that AKT ablation leads to an increased vesseldensity which are however immature and leaky323.As mentioned before, AKT has many downstream targets, one of the most studied is thetuberous sclerosis protein 2 (TSC2) whose phosphorylation leads to mTORC1activation324. Another AKT substrate is eNOS which is phosphorylated on Ser 1179 residueand whose activity generates nitric oxide 325. The activity of GSK3, a protein involved incellular processes such as control of glycogen and protein synthesis, is also controlled byAKT326, 327. The gene transcription regulated by the forkhead box protein O1/3 (FoxO1/3)can be modulated by mTORC2 via AKT328, 329.Two AKT residues must be phosphorylated to induce the full kinase activation in responseto growth factors (e.g. insulin-like growth factor, IGF): Thr 308 in the activation loop (A-loop) and Ser473 in the hydrophobic motif (HM)330. The kinase responsible for the
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modification on Thr308 is the phosphoinositide-dependent protein kinase 1 (PDK1) 331, 332,whereas on Ser473 is PDK2 (later identified as mTORC2) 333-335. However, other kinases canperform PDK2 activities such as Integrin-linked kinase (ILK) 336-338. AKT can also beactivated as consequence of PI3K-independent phosphorylation of its Tyr 176 residue339.AKT is phosphorylated by mTORC2 on two different sites: in the HM on Ser 473 residue andin the turn motif (TM) on Thr 450 residue333-335. The phosphorylation in the TM is stable andtakes place during AKT synthesis, when the polypeptide is still in the ribosome 340 and it isessential for the protein stability334. However, despite different data published, AKT levelsseem to be only slightly affected by mTORC2 ablation probably by the protective action ofthe chaperon protein named heat shock protein 90 (Hsp90) 333, 334.
3.4.2.2. Serum and Glucocorticoid- regulated Kinase 1 (SGK1)The Serum and Glucocorticoid-regulated Kinase 1 (SGK1) is a molecule whose activityregulates many proteins341 mostly involved in cell proliferation 341, 342, survival343,inflammation344, 345, sodium and other ions transport 346.It is activated in response to growth factors or insulin and it is up-regulated by osmoticstress341, 347. SGK1 is phosphorylated by mTORC2 on Ser 422 in the hydrophobic motif(HM)314, whereas less clear is the mTORC2-specific site in the turn motif (TM), probablyThr368.  Deletion of mTORC2 doesn’t lead to SGK1 degradation but can contribute to itsdysregulation leading to an aberrant forkhead box protein O1/3 (FoxO1/3)phosphorylation314. Phosphoinositide-dependent kinase 1 (PDK1) is also involved in SGK1activation: by phosphorylation of the Thr 256 residue it leads to maximal SGK1 activity 341,347.
3.4.2.3 Protein Kinase C alpha (PKCα)Protein kinase C alpha (PKCα) belongs to the PKC family of serine/threonine proteinkinases and leads to the phosphorylation of several targets involved in differentpathways348: for example, it  is responsible for actin cytoskeleton rearrangement 313, 349, 350,cell permeability351 and migration352, 353. Moreover, in endothelial cells, PKCα is able todirectly phosphorylate AKT on Ser 473 and to induce eNOS activity by phosphorylatingSer1179 residue336, 354.PKCα activity can be regulated by the interaction with the cell membrane that increasescalcium and diacylglycerol (DAG) 332, 355. The full PKCα activation also requires thephosphorylation of its activation loop (A-loop) which is catalyzed by thephosphoinositide-dependent kinase 1 (PDK1) 356.
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PKCα phosphorylation in the turn motif (TM) on Thr 638 and in the hydrophobic motif (HM)on Ser657 instead requires mTORC2333, 334. These posttranslational modifications arestrongly decreased or even abolished in RICTOR absence and are important for PKCαmaturation, stability and signaling 313, 333, 334. The heat shock protein 90 (Hsp90) canprevent proteasome-mediated PKCα degradation in RICTOR absence, that takes placeparticularly when the TM is not phosphorylated 333, 334.
3.4.3. The mammalian target of rapamycin (mTOR) in angiogenesisIn many tumor cells the axis PI3K/AKT/mTOR is particularly active 315. The dysregulationof the proteins involved in this network can lead to uncontrolled cell proliferation,migration, survival and metabolism, as it happens in tumor cells 313, 315, 321, 357 . These cellsare also able to produce and secrete large amounts of growth factors (e.g. in hypoxicconditions VEGF) which stimulate aberrant angiogenesis, leading to the tumorvascularization321. Therefore, many treatments for tumors and clinical trials were basedeither on blocking the action of these growth factors on endothelial cells 263, 268, 269 or bytargeting components of the PI3K/AKT/mTOR axis 358, 359. In particular, it was observedthat treatments with rapamycin or rapamycin-based drugs could limit the tumor growthby inhibiting cell proliferation and angiogenesis 360, 361. In parallel to decreasedangiogenesis, the pharmacological inhibition of the PI3K/mTOR pathway, led to a type of“normalization” of the tumor vasculature with vessels characterized by a morephysiological shape, structure and proprieties 362. This normalization enabled better anti-tumor treatment by chemo- and radiotherapy.Interestingly, the use of drugs targeting both mTOR complexes induces a greater inhibitionof the tumor growth and angiogenesis 363. From these in vivo data, the idea that mTORC2might have a specific impact on angiogenesis arose. This hypothesis was supported also by
in vitro data generated in our group: in 2002, we discovered that rapamycin could blockthe sprouts formation in aortic rings and the proliferation of ECs and vSMCs induced bygrowth factors (FGF2 and PDGF) in hypoxic conditions 364. In 2007, we showed that mTORcomplexes mediate the effect of hypoxia on endothelial cells proliferation, mostly via AKTsignaling365. Based on all of these observations, it is evident that mTOR is needed to induceangiogenesis in vivo and in vitro. However, since rapamycin and mTOR-inhibiting drugstarget both mTOR complexes, it is not yet clear whether individual roles for the twocomplexes exist in angiogenesis.
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4.     AIM OF THE THESIS
In the last decade, the number of studies focusing on mTOR increased considerably, due tothe importance of this kinase in several cellular pathways, frequently involved in diseases.Previous results of our group and others clearly showed an important role of mTOR inangiogenesis, a physiological phenomenon which can also lead to the development ofseveral diseases such as cancer 361-365.This kinase, however, is part of two different complexes (mTORC1 and mTORC2) whichhave different functions and substrate specificities. While the role of mTORC1 has beenintensively studied, the implication of mTORC2 in cellular and physiological processesremains to be elucidated in detail. Therefore, many research groups dedicated their effortsin understanding the role of mTORC2 in different tissues and organs. Our group isparticularly interested to determine which function(s) is attributed to mTORC2 inangiogenesis, specifically in the endothelium.
In the studies included in this thesis, we tried to understand:
1. In vivo: the role of endothelial mTORC2 in angiogenesis, using a tissue-specificinducible knockout mouse system and different models of angiogenesis
2. In vitro: cellular and molecular mechanisms that might explain a possible role ofendothelial mTORC2 in angiogenesis using mouse aortic endothelial cells (MAECs)isolated from Rictor-floxed mice.
The mTORC2 deficiency was induced by disruption of the Rictor gene, an essentialmTORC2 component, mediated by genome recombination
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5.     RESULTS – Part A
Endothelial Rictor is crucial for midgestational development and sustained and
extensive FGF2-induced neovascularization in the adult
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5.1. Loss of endothelial homozygous Rictor results in embryonic lethality around
embryonic day (E) 11.5–12.5Whole-body mTORC2 knockout mice are embryonically lethal. Guertin and colleaguessuggested vascular defects as a potential reason for early embryonic death 310, 328. Wefurther investigated the loss of Rictor in endothelial cells during embryogenesis by using aconstitutive VE-Cadherin promoter-driven Cre and LacZ reporter containing Rictorknockout366. The analysis of 101 pups revealed two homozygous Rictor knockout mice,indicating predominant embryonic lethality. Heterozygous Rictor knockout and wild-typemice were born at expected Mendelian ratios ( Figure 20A). Interestingly, the twosurviving RictorΔec mice were females, fertile, and phenotypically normal. When furtherused for breeding, these two RictorΔec mice gave birth only to heterozygous and wild-type
Rictor pups. On E10.5, LacZ reporter-positive  RictorΔec and wild-type embryos displayedendothelial cell-specific CRE recombination, as visualized by β-galactosidase staining inintersegmental vessels, intracranial arteries, and the dorsal aorta. LacZ activity in thedorsal longitudinal anastomotic vessel was clearly visible in wild-type embryos but wasless prominent in RictorΔec embryos, indicating reduced or delayed angiogenesis into theperiphery from intersegmental vessels (Figure 20B). However, RictorΔec embryosgenerally appeared normal and were viable at this time point. We found noticeabledistinct vascular features in few selected but not all RictorΔec embryos compared tocontrols: vascular remodeling around the vitelline artery that usually occurs at this orearlier time-points367 was characterized by the presence of numerous, thin parallelanastomosing vessels which are not observed in wild-type mouse embryos. Furthermorewe found dilated intracranial vessels in RictorΔec but not in controls (Figure 20B).
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Figure 20. Constitutive homozygous endothelial Rictor knockout during embryonic development is
generally lethal.
Rictorflox/flox females were mated with Rictorflox/-; VE-Cadherin-Cre+/-; LacZ reporter +/+ males to generatehomozygous deletion of Rictor in the endothelium. Litter genotypes were determined by qPCR and aredisplayed as total distribution and average number of pups per genotype (n total pups=102, ****P<0.0001,***P<0.001, 1-way ANOVA with Bonferroni multiple comparison) ( A). The abovementioned breeding schemewas used to isolate embryonic day (E) 10.5 wild-type and endothelial Rictor knockout embryos.Representative β-galactosidase staining (blue) of E10.5 embryos (upper panels) shows the active sites of VE-
Cadherin-Cre recombination. Images show E10.5 representative embryos before staining. Arrows on the rightindicate distinct vascular remodeling or dilation in Rictor knockout embryos (B).
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This feature has also been observed in Rictor whole body knockout embryos in the studyby Guertin et al.328. Thus, erythropoiesis and vasculogenesis of the primitive vascularplexus, which is completed on E10.5368, was not modulated by endothelial mTORC2. Toprecisely determine the time point of lethality, overlapping tamoxifen-injection schemes inpregnant mice with homozygous loxed Rictor gene and inducible VE-Cadherin CreERT2recombinase were used (Figure 21A). Injecting tamoxifen three times in pregnant mice,starting at E7.5, produced marked and significant reductions in litter size ( Figure 21B).However, injecting tamoxifen twice at E7.5 did not result in any differences in litter size(Figure 21B). Knockdown of Rictor by 60% is achieved with two injections of tamoxifen,whereas nearly homozygous (92%) knockout is achieved with three injections oftamoxifen every second day369. Thus, with three injections starting on E7.5, knockout of
Rictor was likely to be maximal starting from E11.5–E12.5. On E17.5, one third of theembryos were growth-retarded, and the remaining embryos were absorbed ( Figure 21C).In addition, more than 90% of analyzed embryos were growth-retarded after tamoxifeninjections began on E6.5 and E8.5 (Figure 21C). Interestingly, tamoxifen injections thatbegan on E12.5 and E14.5 had no influence on viability and growth ( Figure 21C).Embryos that were injected with tamoxifen on E8.5 had a body length of approximately 14mm, whereas embryos that were injected on E14.5 had a body length of 19.5 mm. Wild-type embryos at embryonic day 17.5 displayed a body length of 18–22 mm ( Figure 21D).Furthermore, growth-retarded embryos did not display wrinkled skin; instead, the skinwas rather thin, and subcutaneous veins were visible ( Figure 21E). To investigatewhether endothelial-specific Rictor knockout causes a delay in vascularization, embryosreceived three injections of tamoxifen that started on E7.5, after which they weresacrificed at E12.5. The majority of endomucin-stained vascular plexi were present in both
RictoriΔec and control embryos. Again, we detected a few distinct vascular features, such asreduced sprouting angiogenesis in subdermal vessels in the ventral region of RictoriΔecembryos (Figure 21F). Also, the temporary hyaloid vessels in the eye had formedincompletely (Figure 21F). In growth-retarded RictoriΔec mice that were first injected withtamoxifen on E.6.5 and E8.5, ossification centers in the fingers were strongly reduced ormissing when analyzed on E17.5 as compared to embryos that were first injected on E14.5(Figure 21G, alizarin red (bone) and alcian blue (cartilage) staining and quantification ofossification centers below). Embryos that were first injected on E14.5 displayed anossification progress comparable to wild-type mice as demonstrated earlier by Gollner etal.370. Similarly, the progress of ossification in the vertebrae was clearly delayed inembryos that were first injected with tamoxifen on E8.5, and the long bones of the upperand lower limbs were significantly shorter in embryos that received their first tamoxifen
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injections on E6.5 and E8.5 (Figure S1). Furthermore, CD31 staining from skin, brain,skeletal muscle, lung, and colon sections of growth-retarded RictoriΔec mice weremorphologically indistinguishable from sections of wild-type control mice ( Figure S2).
Figure 21. Lethality and growth retardation of induced endothelial Rictor knockout mice peaks around
E12.Tamoxifen (Tx) injection scheme: Three doses of Tx (1 mg, intraperitoneally) were administered to pregnantfemales every 48 hours, beginning on E6.5, E7.5, E8.5, E10.5, E12.5, and E14.5. Pregnant females weresacrificed, and embryos were harvested on E17.5 for further histological analysis. Grey area symbolically
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depicts stepwise Rictor knockout. Control females were injected with corn oil ( A). RictoriΔec mice exhibitdecreased litter size. Statistical analysis of the litter size of individual breedings (n Eday) after three and two Txinjections at different time points (nE6.5 =3, nE7.5 =3, nE8.5 =4, nE10.5 =3, nE12.4 =4, nE14.5 =4,) compared to controls(n=7).  *P<0.05. Student’s t-test (B). Growth retardation and embryonic lethality around midgestation in
RictoriΔec embryos. Statistical analysis of normal, growth retarded, and absorbed embryos per breeding afterTx-injection at different time points. Total litter size for breeding at each time point was set to 100%,nbreedings=3 (C). RictoriΔec embryos display reduced body length on E17.5. Statistical analysis of the length ofsurviving embryos  per litter at different starting time points of Tx injections. n=4 (embryos per time point,length was measured in both extremities), *P<0.01 compared to controls. Student’s t-test ( D). Representativepicture of a E17.5 RictoriΔec embryo that was induced by Tx on E8.5 in comparison to a wild-type embryo ( E).
RictoriΔec embryos display distinct vascular deficits. Pregnant females were injected with three Tx injectionsstarting on E7.5. Embryos were then harvested at E12.5 and stained with the vessel-specific antibody,endomucin. Scale bar=100 µm. Arrows indicate angiogenic sprouts (F). RictoriΔec embryos display a delay inossification. Representative pictures of the upper limbs of embryos stained with alizarin red (bone) and alcianblue (cartilage). Arrows: ossification centers. Below quantification with number of ossification centers infingers upon knock down of Rictor at indicated starting time points of Tx injections. *P < 0.05, **P < 0.01,compared to E14.5; n=4, Mann-Whitney Rank Sum Test (G).
In summary, endothelial Rictor knockout resulted in lethality, which peaked around E12based on analysis of lethality and growth retardation induced by overlapping Tx-injectionregimens. Although Rictor knockout did not affect vascular plexus formation, distinctabnormal vascular features, such as delayed angiogenesis into the periphery, weredetected, and growth retardation was accompanied by delayed bone ossification infingers, toes and vertebrae.
5.2. Endothelial-specific Rictor knockout has no obvious effect on viability and
weight gain during adolescence into adulthoodWe proceeded to analyze the general requirement of endothelial mTORC2/RICTOR usingthe inducible VE-Cadherin-driven CreERT2 variant (RictoriΔec) during adolescence from theage of 4 weeks (at the time of tamoxifen-induced Rictor knockout) to adulthood, up to anage of 28 weeks. No statistically significant differences in weight gain were observedbetween genotypes and genders ( Figure 22A). Furthermore, all groups displayed normalhealth and viability. At the end of the weight study, the aorta from male control and
RictoriΔec mice were removed, the endothelium was scraped and Rictor mRNA levels weredetermined by quantitative polymerase chain reaction (qPCR) to show stable, efficient,and significant knockdown of Rictor (Figure 22B). Adolescent double transgenic mice(Cre+/+; Rictorlox/lox) also displayed specific CRE expression in capillaries from the mousedermal skin muscle, as shown by estrogen receptor-specific staining in tissues that wereused for intravital experiments (Figure 22C). Although VE-Cadherin promoter-driven CRE
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recombination may also affect hematopoietic development 369, we found similarhematological profiles in 8-week-old control and RictoriΔec mice. These profiles werecomparable to those of healthy C57/Bl6 mice ( Figure S3).
Figure 22. Rictor knockout does not affect weight gain and viability in adolescent mice.Body weights were followed in male and female mice over a period of 27 weeks after induction of knockout orcontrol on week 4. No significant differences were detected in male or female RictoriΔec mice compared tocontrol mice. n=10 per genotype and gender, 2-way ANOVA with group-wise comparison. All mice displayednormal health, behavior, and viability (A). After 27 weeks, the aortae of a subset of male mice were excised andisolated. The endothelial layer was scraped, and RNA was extracted for quantitative polymerase chain reaction(qRT-PCR) analysis to test for efficient excision of Rictor (n=3/2, *P<0.05. 2-tailed T-test), and qualitatively forpurity of endothelial tissue (endothelial marker Pecam1, smooth muscle marker αSma). Total aorta mRNA wasused as comparative control (B). Representative immunostainings for estrogen receptor 2 (red fluorescence)in histological sections of the skinfold from 10-week-old RictoriΔec mice demonstrates specific expression ofCreERT2 recombinase associated with capillaries (C).
These experiments demonstrate that the stable ablation of endothelial mTORC2 inadolescent mice, which persisted until late adulthood, did not cause obvious generalhealth problems, as supported by normal hematological profiles, weight gain, and viability.
51
5.3. Rictor knockout in mouse aortic endothelial cells (MAEC) differentially disables
the formation of capillary-like endothelial networks.Our results so far suggested, that knockout of Rictor in endothelial cells has no obviouseffects on the development during adolescence in mice and therefore may not affect basicphysiologic parameters of the endothelial cell such as survival and homeostatic functionsin the existing and developing vasculature. Before continuing investigations about the roleof mTORC2 in activated endothelium in vivo, we used an in vitro assay to determine theangiogenic response of control and Rictor knockout mouse aortic endothelial cells to thetwo major angiogenic molecules FGF and VEGF (Figure S4). After plating on a basementmembrane (BM) matrix gel, endothelial cells build capillary-like tubes with a lumen withina short time. Cells initially attach to the matrix and then migrate towards each other, afterwhich they align and form tubes 371. We found that control MAEC formed connected mastersegments in the presence of the diluent (1% fetal calf serum [FCS]), FGF2 and VEGFA(Figure 23A). The ability of Rictor knockout MAEC (Rictor KO MAEC) to build stablecontacts and connecting tubes was substantially disabled: Rictor knockout preventedMAEC from forming capillary-like tubes in unstimulated conditions. Upon FGF2stimulation, Rictor  KO MAEC arranged into star-like shapes, with sprouts extending fromcell clusters, but did not establish contacts to other cell clusters and formed significantlyless master segments compared to control (Figure 23A). A stable CRE-induced Rictorknockout with blunted AKT phosphorylation on Ser 473 was detected during theseexperiments (Figure 23A). In contrast to the study by Wang et al.372, VEGFA stimulationpartially rescued endothelial network formation in Rictor KO MAEC. Rictor KO MAECswere able to form some substantial networks and organized tubes, albeit in in numbersthat were small and similar to those of control MAECs ( Figure 23A). To further evaluatedifferences in mTORC2/RICTOR requirement for FGF2- and VEGFA-induced tubeformation in vitro, we performed co-culture experiments. Control and Rictor KO MAECwere mixed at a 1:1 ratio. VEGFA-stimulated Rictor KO MAECs established mastersegments autonomously without adhering to control MAECs ( Figure 23B; on the right:arrows indicating individual Rictor KO master segments). FGF2-stimulated Rictor KOMAECs were always found as part of master segments that were formed by control MAECs.Thus, FGF2-induced cell clusters projected sprouts but were unable to form maturecapillary-like networks in Rictor KO MAEC cells (Figure 23B; on the left: arrows indicatingunconnected Rictor KO sprouts).
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As we found that the angiogenic response to FGF2 was significantly more affected by
Rictor knockout than that to VEGFA, we further focused on FGF2-mediated responses inendothelial cells and angiogenesis assays in vivo in this study.
Figure 23. Rictor knockout in mouse aortic endothelial cells (MAEC) decreases endothelial network
formation.Control and Rictor knockout MAEC (Rictor KO MAEC) were seeded on growth factor-reduced matrigel andstimulated with diluent (1% fetal calf serum [FCS]), FGF2 (25 ng/ml), and vascular endothelial growth factor(VEGFA; 25 ng/ml). Representative micrographs show endothelial network formation after 18 hours.Quantification (total number of master segments that connect to at least two other segments) of endothelialtube formation from three experiments is shown below. (Bars; mean and SEM, n exp=3, *P<0.05 versus control.Paired T-Test). Western blot lower right showing RICTOR, Phospho-AKT Ser 473, and total AKT expression fromcontrol (AdCre-) and Rictor KO (AdCre+) MAECs (A). Endothelial network formation of Rictor KO MAEC afterco-culture with control MAEC. Control and Rictor KO MAEC were labeled with green and red tracking dyes,respectively, mixed at a 1:1 ratio, and seeded on growth factor-reduced matrigel. Tube formations ofendothelial cultures after 18-hours stimulation with FGF2 or VEGFA were photographed on a fluorescencemicroscope (4× magnification). Arrows mark endothelial segments composed of Rictor KO MAEC only inVEGFA-treated cultures, whereas Rictor KO MAEC could only participate in segment formation through
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association with control cells in FGF2-treated cultures. FGF2-treated Rictor KO MAEC typically formed star-shaped centers with omni-directional sprouting and no connection to neighboring centers ( B).
5.4. FGF2 amplifies RICTOR protein and RICTOR-dependent phosphorylation of AKT
on Serine 473 and PKCα on Serine 657Interestingly, we found a consistently low expression of RICTOR in starved, unstimulatedand subconfluent MAEC isolate, whereas FGF2 amplified RICTOR protein levels.Quantification demonstrated a significant increase in RICTOR protein at 5 ng/ml of FGF2peaking at an 8-fold expression compared to diluent at 50 ng/ml of FGF2. ( Figure 24A,upper left panels). We assessed how FGF2-induced signaling is altered in mTORC2-deficient endothelial cells and focused on one of the main mTORC2 downstream targets,PKCα and AKT333. In control MAEC, FGF2 induced the dose-dependent phosphorylation ofthe hydrophobic motif (HM) of PKCα on Ser 657. Interestingly, deletion of Rictor stronglydecreased PKCα protein levels and accordingly blunted the phosphorylation of the HM ofPKCα in response to FGF2, FCS, and insulin ( Figure 24A). PKCα signaling was stronglydisabled in Rictor KO MAEC, and this was most likely a result of total PKCα proteindestabilization and degradation due to absent phosphorylation 333. We then assessed theimpact of Rictor deletion in MAEC on mTORC downstream target protein kinase AKT (alsoknown as PKB). The phosphorylation of the activation loop (A-loop) on Thr 308 byphosphoinositide-dependent kinase 1 (PDK1) and of the HM at Ser 473 of AKT by mTORC2results in AKT activation 335,373. In control MAEC, FGF2 induced a marked and dose-dependent phosphorylation of AKT on Ser 473 that peaked at 25 ng/ml of FGF2. Rictorknockout efficiently and significantly blunted FGF2-, FCS-, and insulin-induced AKTphosphorylation (Figure 24A, quantification to the right). The disruption of mTORC2 hasbeen shown to decrease the A-loop phosphorylation of AKT in some cancer cell lines 335. Incontrol MAEC, A-loop phosphorylation was robustly induced by FGF2, FCS, and insulin.After Rictor knockout, we did not detect a significant reduction in the A-loopphosphorylation of AKT ( Figure 24A). These results are consistent with reports in cells ortissues that were derived from mice with genetic deletions of mTORC2 components. Inthese mice, A-loop phosphorylation was not disrupted in the absence of HMphosphorylation328,329,333.The depletion of AKT phosphorylation by Rictor knockout may influence mTORC1signaling. AKT phosphorylates and inhibits tuberous sclerosis 2 (also known as tuberin),thus resulting in the activation of mTORC1-S6 kinase 1 (S6K1) 324. We found that FGF2dose-dependently promoted S6K1 phosphorylation in control MAEC. After Rictorknockout, a minor but insignificant reduction in FGF2-induced S6K1 phosphorylation wasdetected (Figure 24A). No differences in the phosphorylation of extracellular signal-
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regulated kinase 1 and 2 (Erk1/2) by the FGF2 gradient were observed in control MAECand Rictor KO MAEC (Figure 24A)374.A close cross-talk exists among FGF2 and the different members of the VEGF family duringangiogenesis and several studies have suggested that FGF2 induces neovascularizationindirectly by activation of the VEGF/VEGFR system 375. We confirmed that Vegfa mRNAsubstantially increased after FGF2 stimulation, yet Rictor knockout did not affect thisinduction. To investigate whether endothelial mTORC2 might modulate in vitroangiogenesis in response to FGF2 by regulation of VEGF receptors, we measured themRNA-levels of the two main VEGF-receptors Flt1 (VEGFR1), which is characteristic forstalk cells and quiescent endothelium, and Kdr (VEGFR2), upregulated in tip cells376.Interestingly we found a strong FGF2-induced upregulation of the membrane form of Flt1(mFlt1) and an even stronger induction of soluble Flt1 receptor (sFlt1) mRNA (Figure
24B). Kdr message was present and decreased after FGF-stimulation ( Figure 24B).However, Rictor knockout cells induced mFlt1 and sFlt1 and reduced Kdr messagecongruent to control cells after FGF2 stimulation, which argues against endothelial tip-stalk-cell modulation by mTORC2. FGF2 also stimulates VEGFA in endothelial cells offorming capillaries and cultured aortic endothelial cells 97. Similarly, FGF receptor 1 (Fgfr1)message equally increased in control and Rictor KO MAEC. The decrease in PKCα proteinafter Rictor knockout was due to posttranscriptional mechanisms as PKCα geneexpression was equal in control and Rictor KO MAEC (Figure 24B).Furthermore, we did not observe any significant differences in endothelial proliferationover a period of 72 hours in the dose response to FGF2 ( Figure 24C) or FGF2-induced-migration in a wound assay (Figure 24D). However, a weak but significant (P<0.05,nexp=4) reduction in proliferation was detected in the presence of FCS ( Figure 24C).Similarly, we found a significant reduction in VEGFA-induced proliferation by Rictorknockout (Figure S5).In conclusion, FGF2 amplified RICTOR protein in control MAEC and Rictor deletion inFGF2-stimulated MAEC strongly blunted PKCα signaling and reduced AKT activity bydepleting Ser473 phosphorylation. Rictor deletion had no effects on mTORC1 signaling andFGF2-induced proliferation, migration nor did it interfere with FGF2-induced modulationof Flt1, Kdr and Vegfa expression levels.
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Figure 24. FGF2 amplifies RICTOR protein and Rictor-dependent phosphorylation of AKT on Ser473 and
PKCα on Ser657.Subconfluent and starved control and Rictor KO MAEC were stimulated for 15 min with increasing doses (5–50ng/ml) of FGF2. As controls, MAEC were treated with 10% FCS or 1 μg/ml insulin (Ins). Western blots showthe expression of RICTOR and downstream and targets of mTORC2. Low expression of RICTOR is detected instarved, unstimulated and confluent control MAEC, whereas FGF2 increased RICTOR protein levels.Quantification demonstrated a significant increase in RICTOR protein at 5 ng/ml of FGF2 peaking at an 8-foldexpression compared to diluent at 50 ng/ml of FGF2 in 3 repeated experiments in a MAEC isolate.(control=white bars, nexp=3, *P<0.05, **P<0.001, 1-way ANOVA with Bonferroni multiple comparison, upperleft panels). Furthermore, PKCα protein was nearly absent in Rictor KO MAEC compared to control (middlepanels). Densitometric quantification shows dose-dependent AKT phosphorylation on Ser 473 in response toFGF2 in control MAEC with significant blunting in Rictor KO MAEC and similar reductions in response to FCSand Ins (right panels, nexp=3, *P<0.05, **P<0.01, ***P<0.001, repeated measures ANOVA). Lower middle blotsshow no changes in S6K1 phosphorylation on Thr 389 compared to total S6K1 and phosphorylation of p42/44
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MAPK on Thr202/Tyr204 compared to total p42/44 MAPK after Rictor knockout (A). Three individual confluentand starved control and Rictor KO MAEC isolates were stimulated for 1–6 hours with 25 ng/ml FGF2. mRNAexpression for membrane-bound and soluble VEGF receptor 1 (mFLT1, sFlt1), VEGF receptor 2 (Kdr), Vegfa(Vegfa), FGF receptor 1 (Fgfr1) and protein kinase Cα (PKCα) were detected by quantitative real-time PCR(n=3, ns knockout versus control, repeated measures ANOVA) ( B). Control and Rictor KO MAEC were seededsubconfluently, cultured for 25 hours in growth medium with 1% FCS, and then stimulated with FGF2 or 10%FCS for 3 days. Cell proliferation was measured by WST-1 reagent. Absolute proliferation values(Absorption=A450nm-A650nm) in FGF2-stimulated control (open circles) or Rictor KO (filled squares) MAEC arepresented. No significant differences were observed for FGF2-stimulated proliferation after Rictor knockout(n=3, repeated measures ANOVA). In response to 10% FCS (right), proliferation of Rictor KO MAEC wassignificantly lower compared to that of control MAEC (n exp=3, two-tailed T-test) (C). Control and Rictor KOMAECs were grown to confluency, cultured for 25 hours in growth medium with 0.5% FCS, and a uniformscratch applied to the monolayer. Migration of MAECs was measured after FGF2 (25ng/ml) or diluentadministration for 1, 3, 6 and 9 hours (wound completely closed=1, n=3, no differences between groups byrepeated measures ANOVA) (D).
5.5. The structure of the capillary bed of the striated skin muscle is not altered by
endothelial-specific Rictor knockoutIn preparation to study mTORC2-dependent vascular changes in response to woundingand FGF2 in vivo, we first recorded the capillary morphology in the existing striated skinmuscle (Panniculus carnosus) vascular bed as baseline. To do so we surgically mounted adorsal skinfold chamber 377, 378 to 8-week-old control and RictoriΔec mice. We observed thatthe baseline capillary bed, which was recorded 3 days post-chamber surgery, appearedvery similar in 8-week-old control and RictoriΔec mice (Figure 25A). Analysis of allcapillary diameters measured at baseline did not reveal significant differences ( Figure
25A). In both experimental groups, the vascular bed consisting of the panniculus carnosuswith its capillary structures was organized in the typical parallel orientation, and thesubcutaneous layer with draining arterioles and venules exhibited the typical perfusionpattern of the dorsal skinfold chamber capillaries, as observed in previous studies 377.Thus, ablation of endothelial Rictor did not interfere with the development or directlyobservable functionality of the intact, unstimulated dermal microvasculature in adolescentmice, which is in line our observation of normal growth, viability and weight gain ofadolescent mice lacking endothelial Rictor.
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Figure 25. Rictor knockout disables a sustained increase in skin capillary diameters and restricts
extensive capillary remodeling in response to FGF2.Stacked frames of representative videos of the capillary vasculature were recorded through the dorsal skinfoldchamber by intravital fluorescence microscopy. Baseline capillary bed of the skin muscle was assessed in 10-week-old mice (6 weeks after knockout induction) by intravital microscopy through the unmodified dorsal
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skinfold chamber. Upper (20× magnification) and lower micrographs (10×) display representative skincapillary beds of control (left) and RictoriΔec (right) mice. Capillary diameters from 10 control and RictoriΔecmice were quantified and pooled for statistical analysis (n=253/206, no differences between groups , 2-tailedT-test and Whisker plot, indicating median, 25% percentile and total range to the right). Color scheme appliesfor whole figure 6 and is displayed in upper right corner (A). Wound response of the capillary bed. Skin musclecapillary structure from day 1, 2, 4 and day 7 in control (left) and RictoriΔec mice (right) after wound sealingwith heparin-containing matrigel (20× magnification). Capillary diameters from 4 control and RictoriΔec micewere quantified and pooled for statistical analysis by 1-way ANOVA followed by Bonferroni multiplecomparison (Scatter plot with medians on the below; number of capillaries (n capillaries) are indicated below theX-axis, ****P<0.0001) (B). Heterogeneous capillary diameter increases in the FGF2-stimulated capillary bed.Skin muscle capillary structure from day 1, 2, 4 and day 7 in control (left) and RictoriΔec mice (right) afterwound sealing with FGF2 (1.5 µg/ml; heparin-containing matrigel, 20× magnification). Capillary diametersfrom 7 control and RictoriΔec mice were quantified and pooled for statistical analysis by 1-way ANOVA followedby Bonferroni multiple comparison (Scatter plot and medians below; number of capillaries are indicatedbelow the X-axis, ****P<0.0001) (C). Capillary remodeling in the FGF2-stimulated capillary bed. The line graphdisplays the normalized distribution of capillaries (nmax=100) resolved in a 1-µm range after FGF2 stimulationfor 7 days and illustrates differences in remodeling between groups. Micrograph to the right shows 10xmagnification of the vascular bed of control and RictoriΔec mice after 7 days of FGF2 exposure (D).
5.6. Wounding-induced capillary diameter remodeling is not impaired by
endothelial-specific Rictor knockoutWe then modified this chamber by additionally removing cutis and subcutis on theopposite side of the observation window. This defect was sealed by growth factor-reducedmatrigel (Figure S6). In the first set of experiments, we included diluent (heparin) inmatrigel to assess baseline alterations as a response to wound healing processes withoutexogenous growth factor stimulation. Capillaries were observed and recorded on a dailybasis by intravital microscopy up to 7 days after matrigel sealing ( Figure 25B). Vascularmorphological parameters were quantified in vessels where perfusion was observable.The vessels encompassed diameters ranging from 4 to 20 μm, thus capillaries and somesmall arterioles or venules. Capillary diameters significantly increased from day 1, 2, 4 and7 compared to the baseline by about 2 µm in average for both control and RictoriΔeccapillary diameters (Figure 25B). Importantly, the microvasculature of the panniculus
carnosus responded similarly to wounding and matrigel sealing in control and RictoriΔecmice as we did not detect significant differences compared to controls at days 1, 2, 3, and 7(Figure 25B).
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5.7. Endothelial-specific Rictor knockout limits increases in the capillary diameter
of existing skin vasculature in response to high doses of FGF2.To assess remodeling in terms of individual increases in capillary diameters in response tostrong angiogenic stimulation, we exposed the existing capillary bed to a high dose ofFGF2 (1.5 μg/ml). We focused on FGF2, since we found that Rictor deletion specificallydisabled FGF2- but not VEGFA-dependent angiogenesis in vitro as shown earlier in thismanuscript. Furthermore, FGF2 also promotes maturation of larger vessels such asarterioles379. Intravital recordings through the dorsal skinfold chamber in control and
RictoriΔec revealed that diameters increased at day 1 and day 2 after FGF2 exposure(Figure 25C , day 1 and 2). In both groups, diameters had increased for about 3.5 µm andwe found no statistical difference between groups after testing by Bonferroni multiplecomparisons (Figure 25C). At days 4 and 7, capillary diameters further increased in thecontrol group (P<0.0001 when comparing diameters at day 1 to diameters at day 4 of thecontrol group). In addition, tortuous and bulbous vascular structures developed, whichwere observed in capillaries and small draining arterioles and venules ( Figure 25C, day 4
and 7). In RictoriΔec mice, however, FGF2-induced capillary enlargement stopped andrather regressed after day 2. Statistically, capillary diameters at days 4 were not differentfrom those measured at day 1. Diameters measured on day 4 and 7 in RictoriΔec weresignificantly smaller compared to the control group on those days ( Figure 25C). Weobserved, that at the end of the recording the vascular bed in RictoriΔec mice underwent afar more restrained and different mode of remodeling. Thin-connecting anastomosesemerged between capillaries and draining arterioles in RictoriΔec mice, and the orientationof capillaries remained largely parallel (Figure 25C and D, day 7). The dilated andtortuous capillary structures that developed in control mice after longer (4 and 7 days)exposure to FGF2 are also found in vascularized tumors, which in addition exhibithyperpermeability 380. We assessed vessel leakage of the FGF2-stimulated skin vascularbed on day 7 by intravenously injecting fluorescently labeled ricinus communis agglutinin I(RCA-I)381. Preliminary data could however not support an obvious decrease inpermeability by endothelial Rictor deletion as plasma leakage points were present incapillary structures from both control and RictoriΔec mice to a similar extent ( Figure S7).Taken together, loss of endothelial Rictor normalized vascular structure after 4 days ofexposure to FGF2 and prevented the formation of a heterogeneous, irregularmicrovascular bed as seen in controls ( Figure 25D). This suggests that endothelialmTORC2 is central to the FGF2-mediated remodeling response that creates larger andheterogeneously sized capillaries and small arterioles in the existing skin capillary bedbeyond day 4.
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5.8. Endothelial-specific Rictor knockout strongly reduces FGF2-induced
neovascularization in matrigel plugs and prevents local hemorrhageAs technical limitations disabled us to monitor sprouting angiogenesis in the dorsalskinfold chamber, we used the matrigel plug angiogenesis assay to assess whetherendothelial mTORC2 deficiency may alter de novo vascularization in adult mice in vivo inresponse to strong stimulation by FGF2 (1.5 µg/ml). Concentrations of FGF2 in this rangehave been used previously to achieve maximal neovascularization after 7 days 382 and toachieve macroscopically a hemorrhagic appearance ( Figure S8). Knockout of Rictor in theendothelium was induced during adolescence in RictoriΔec mice. At 7 days afterimplantation, blood-containing microvessels and signs of hemorrhage weremacroscopically evident in FGF2-containing plugs from control mice. In contrast, FGF2-containing plugs from RictoriΔec mice displayed homogenous, unobtrusive vascularization.An estimation of blood content by optical densitometry demonstrated a significantdecrease after Rictor knockout in FGF2 containing plugs compared to control plugs(Figure 26A, 1st row). FGF2-induced vessels protruded to about 800 μm from the surfaceof the plug into the center in plugs from control mice, whereas microvessels protrudedsignificantly less to only about 300 μm in plugs from RictoriΔec mice. FGF2-inducedmicrovessel protrusion into the plugs from RictoriΔec mice was not completely abolished aswe calculated a significant difference to diluent containing plugs ( Figure 26A, 2nd row).The presence of leaked erythrocytes in the FGF2-containing plugs from control micedemonstrated local hemorrhage (Figure 26B, left micrographs). In contrast, themicrovasculature in FGF2-containing plugs from  RictoriΔec mice was composed ofhomogenously small capillaries with no evidence of hemorrhage ( Figure 26B , rightmicrographs). During the 7 days of FGF2 administration, the matrigel plug wasencapsulated by a thin layer of stromal tissue that also contained arterioles and venules.We found similar vessel densities in plugs from both experimental groups (data notshown), whereas the luminal diameter was significantly smaller in vessels of the stromalcapsule from RictoriΔec mice compared with control mice. No stromal vessels were found indiluent containing plugs from both groups ( Figure 26A, 3rd row). Angiogenesis occurringduring postnatal development is usually connected with inflammation 383. Macrophageswere demonstrated to promote angiogenesis via FGFs and placental growth factorsignaling383 or by the release of pro-angiogenic molecules383, 85. We therefore investigatedby CD68 immunostaining whether the stromal halo around the plugs may contain varyingamounts of macrophages that could influence de novo angiogenesis in our experimentalsetting. However, we found no significant differences in the ratio between CD68 + cells tototal cell nuclei in the peripheral stroma when comparing diluent and FGF2-containingplugs from both groups (Figure 26A, last row). The total amount of CD68+ cells per field
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counted was also not significantly modulated, however we noticed a trend towards highermacrophage count in stromal halos around FGF2-containing matrigel plugs from RictoriΔecmice (Figure 26A, last row).
Figure 26. Fibroblast growth factor 2(FGF2)-induced angiogenesis in matrigel plugs is reduced in
RictoriΔec mice.Matrigel containing heparin (diluent) or 1.5 μg/ml FGF2 with heparin (FGF2) was injected subcutaneously intothe ventral flank of 8-week-old male control and RictoriΔec mice. The plugs were removed 7 days later andanalyzed. Representative macro-photographs (scale bar=1mm) of matrigel plugs from control (left) and
RictoriΔec mice (right) are displayed. Estimation of blood content by optical densitometry is shown on the right(nplugs=4; **P<0.01; 1-way ANOVA with Bonferroni multiple comparison) ( A, 1st row). Paraffin-embedded,diluent and FGF2-containing plugs were sectioned horizontally and immunostained for CD31 (brown) andhaematoxylin (blue/nuclei). Representative micrographs show 10× magnification and display the depth ofnewly in grown microvessels from the surface towards the center of the diluent and FGF2 containing matrigelplug. Quantification to the right displays the significant reduction in the ingrowth (μm) of neo-vessels intoplugs from RictoriΔec mice compared to control mice (nplugs =4/7; **P<0.01, ****P<0.0001; 1-way ANOVA with
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Bonferroni multiple comparison test) (A, 2nd row). Representative micrographs of peripheral stroma coveringdiluent and FGF2-containing matrigel plugs from control and RictoriΔec mice. The area and the number ofidentifiable inner microvessel diameters were measured. No vessels were found in peripheral stroma coveringdiluent-containing plugs. A significant reduction in the inner luminal diameter in stromal vessels from FGF2-containing matrigel plugs from RictoriΔec mice was detected compared with those from control mice. (graph tothe right; nplugs =3; *P<0.05;2-tailed T-test ) (A, 3rd row). Representative micrographs of macrophage markerCD68-immunostainings of peripheral stroma and matrigel. Graphs to the right show ratio of CD68 +/total cellnuclei in the stroma, and average of CD68+cells per field counted in the stroma (nplugs =4, no significantdifferences found after 1-way ANOVA/Bonferroni multiple comparison test) ( A, 4th row).  Representativemicrographs displaying haematoxylin and eosin stained (H&E) matrigel areas showing local leakage andhemorrhagic areas in FGF2 containing plugs from control mice compared to plugs from RictoriΔec mice (uppermicrographs). Lower micrographs show higher magnification of CD31-stained matrigel areas. Arrowheadspoint to local spots of leaked erythrocytes in FGF2-containg control plugs ( B). Confluent and starved controland Rictor KO MAECs were stimulated for 1 and 24 hours with 25 ng/ml FGF2 or diluent. mRNA expression of
monocyte-attracting protein 1 (Mcp1), vascular and inducible cell adhesion molecules 1 (Vcam1, Icam1) wasdetected by quantitative real-time PCR (n=3; *P<0.05; 1-way ANOVA with Bonferroni multiple comparisontest) (C).
To further investigate the possibility of a mild FGF2-dependent pro-inflammatory stateafter endothelial Rictor knockout we measured the mRNA levels of monocyte-attracting
protein 1 (Mcp1) and vascular- and inducible cell adhesion molecules  (Vcam1, Icam1) inMAECs. FGF2 increased Vcam1 mRNA after 24 hours similarly in both control and  Rictorknockout MAECs. A slight and insignificant increase for Icam1 mRNA was observed. FGF2robustly (ca. 6.6 fold) induced Mcp1 mRNA in control and Rictor knockout MAECs.Interestingly, Mcp1 mRNA remained at high levels (ca. 5.3 fold induction) after 24h ofFGF2 stimulation and was significantly higher compared to controls (3.3 fold) at this time-point (Figure 26C). Thus, it is unlikely, that the strong reduction of FGF2-inducedangiogenesis into matrigel plugs along with ‘normalized’ microvessel features by deletionof endothelial Rictor in vivo is caused by an altered inflammatory response.Taken together, we observe a dense, heterogeneous neo-vasculature with several patchesof hemorrhage indicating disrupted or leaky capillaries that formed after 7 days of FGF2-exposure in control mice. In contrast endothelial Rictor knockout strongly andsignificantly reduced neo-vessel ingrowth in response to FGF2 with capillaries remaininghomogenously small, with no evidence of hemorrhagic spots.
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5.9     Supplementary data
Figure S1. RictoriΔec embryos display a delay in ossification.Quantification of length of long bones of the upper limb (humerus, radius und ulna) and lower limb (femur,tibia and fibula) of endothelial specific Rictor deficient embryos injected with Tx at E6.5 (white bars), E8.5(grey bars) and E14.5 (dark bars) as starting time point. n=4, Students t-test ** p <0 .01 * p < 0.05 compared toE14.5 (A). Representative pictures of the lower spine of embryos stained with alizarin red (bone) and alcianblue (cartilage) for skeletal analysis indicated starting time points for Tx injections. Dotted line: borderossificated vertebrae (B). Statistical analysis of diameter of ossification centers in lumbar vertebrae uponknock out of Rictor at indicated starting time points compared to E14.5. n=4, Mann-Whitney Rank Sum Test **p < 0.01 (C).
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Figure S2. Histological analysis of RictoriΔec embryos with Tx-injections starting at E8.5 and E14.5 in
comparison to control embryos.Embryos were harvested at E17.5, fixed, embedded in paraffin and longitudinally sections wereimmunohistologically stained with anti CD31 antibody to detect endothelium. A: skin, B: brain, C: skeletalmuscle, D: lung and E: colon. CD31, brown; nuclear counterstain, blue. Scale bar = 100 mm.
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Figure S3. Endothelial Rictor knockout does not modulate hematological profile.Hematological profile (Count of leukocytes, neutrophils, lymphocytes, monocytes and eosinophils) wasassessed from 10 weeks old Cornoil and Tamoxifen/Cornoil-injected male Cre +/+; Rictorlox/lox mice. Linebetween bars indicates normal range of parameters for C57/Bl6 mice
Figure S4. Characterization of endothelial cells.Fluorescent Immune-staining (red) of a representative endothelial cell isolate for endothelial cell markers vonWillebrand Factor (vWF) and VEGF receptor 1 (Flt1). The 40x magnification of vWF-staining shows a vWF-typical granular pattern. As negative control, a staining without primary antibody is shown.
Flt1
40×10×vWF
10x 10x
vWF
neg. control
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Figure S5. Endothelial Rictor KO decreases VEGFA-induced MAEC proliferation.Control and Rictor KO MAEC were seeded subconfluently, cultured for 25 hours in growth medium with 1%FCS and then stimulated with diluent, 10 ng/ml and 100 ng/ml of VEGFA. Cell proliferation was measured byWST-1 reagent. Points (±SE) represent absolute proliferation values (Absorption=A450nm-A650nm) in FGF2stimulated wild-type (circles) or Rictor KO (squares) MAEC. Proliferation was significantly (P<0.001, n exp=3)decreased in Rictor KO MAEC compared to controls at 100 ng/ml VEGFA stimulation.
Figure S6. Modification of the dorsal skinfold chamber.Skin was detached from the underlying muscle and removed in a circular area of 7 mm in diameter from theside opposite to the observation window of the chamber. This defect on the back of the chamber was sealedwith 20 µl growth factor-reduced matrigel containing heparin (5 IU) with or without FGF2 (1.5 µg/ml).Afterwards, it was covered with a glass cover slip incorporated into the titanium frame.
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Control   FGF2, day 7 RictoriΔec
Figure S7. Fluorescent intravital staining for ricinus communis agglutinin I (RCA-I).RCA-I is a galactose-binding lectin from castor beans, that binds to endothelial cells at sites of plasma leakage.Methods: 50 µl (1 µg/µl) of TRITC-RCA-I (Vector labs) in PBS was injected via tail vein in anesthetized micecarrying a dorsal skinfold chamber for 30 min. Then, mice were euthanized and skin muscle dissected from theskinfold chamber observation window, and mounted on coverslips. Fluorescence was recorded by optical-gridsectioning of ca. 10×3 µm sections (Zeiss, Apotome 2, 25x magnification). Inverted image of orthogonalprojections of are shown below (blue=leakage points, arrowheads mark regions with increased positivestaining). Pilot experiment (n=2).
Figure S8. Dose response of FGF2-matrigel plugs in control mice.Diluent, 0.5 μg/ml and 1.5 μg/ml FGF2 containing matrigel plugs were implanted in each flank of each mouse.For experiments, plugs were removed 7 days post implantation and analyzed.
diluent 0.5 mg/ml FGF2 1.5 mg/ml FGF2
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6.     RESULTS – Part B
6.1. Endothelial cell culture system
6.1.1. Mouse aortic endothelial cells isolated by aortic rings are positive for the EC
markers VE-Cadherin and von Willebrand FactorThe three different mouse aortic endothelial cell (MAEC) isolates used during this PhD-study were obtained from the aortae of three 8 weeks old male mice (MAEC ISO1-ISO2-ISO3). The aortic endothelial cells sprouted from aortic rings that were embedded into afibrin gel, proliferated and migrated into the three-dimensional surrounding afterendothelial growth factor-stimulation (Figure 27). After subculture and up to two monthsof continuous growth, a sufficient amount of cells with passage numbers between 6 and 8were isolated and characterized.
Figure 27. MAECs sprouting from aortic rings.Micrographs of aortic ring embedded in Fibrin gel with cells sprouting out of the ring seven days after explant(4x and 10x magnification).
Endothelial morphology was a first feature considered in order to characterize theisolated cells: the isolated cells formed cobblestone-like monolayers which is a typicalfeature of cell-contact mediated growth arrest in endothelial cells ( Figure 28)21.
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Figure 28. MAECs monolayer.Cobblestone monolayer formed by the isolated cells growing in full medium, passage number 8 (magnification4×).Cell isolates displaying cobblestone-morphology were further characterized by thepresence of endothelial cell markers. Molecules frequently used to identify endothelialcells are VE-Cadherin384, TIE2385, CD31 and CD34386. We assessed their expression on thetranscriptional level by real-time PCR. The cells (ISO1, ISO2 control, ISO2 knockout andISO3) were then grown in full medium until confluence. RNA was extracted and the real-time PCR performed. As a negative control the RNA extracted from adipocytes was used.As a positive control RNA extracted from the aortic arch (AArch), which containsendothelial cells, smooth muscle cells, fibroblasts and perivascular cells, was used.Furthermore RNA from commercially available MAECs isolated by magnetic sorting withthe same passage number was also used as positive control. All cell isolates were stronglypositive for the important endothelial cell marker VE-Cadherin. Cd34, an antigen expressedin EC and endothelial progenitor cells 386, was detected at low levels (Figure 29). We didnot detect gene expression of the typical endothelial cell marker Cd31 (also known as
Pecam1) including splice variants in our cells. Similarly expression of the angiopoietinreceptor Tie2 was not detected.After endothelial cells are extracted from an in vivo environment and cultured in vitro asmonoculture, down-regulation of many genes has been reported. Human tonsilsendothelial cells lost specialized characteristics, such as the marker DARC or other ECsmarkers such as VEGFR3, SelE or vWF already 2 days after isolation 387. ECs might downregulate the expression of these genes through epigenetic modulation during the processof in vitro cultivation due to the absence of the natural vascular bed 388.
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Figure 29. Characterization of the isolated MAECs.Real-time PCR of Cd31, Cd34, Tie2 and VE-Cadherin expression in the three cell isolates (ISO1, ISO2 presentedas variant Control and Rictor knockout, ISO3), adipocytes, aortic arch and EC (isolated by MACS).
Low levels of Sm22α, a marker for SMCs, were detected in the cultured cell isolates, whencompared to the levels observed in the aortic arch or in the ECs-SMCs co-culture (shortlynamed SMC), suggesting that in isolated cells some SMCs are present ( Figure 30).
Figure 30. SMCs contamination assessment.Real-time PCR for Sm22α mRNA levels in the three cell isolates (ISO1, ISO2C, ISO2K, ISO3) compared to aorticarch, adipocytes, SMCs-ECs co-culture and ECs (isolated by magnetic sorting).
On the protein level, MAEC isolates were positive for a further EC marker, von WillebrandFactor (vWF)386 as seen by immune fluorescence staining (data produced by Dr. Humar,
Figure S4).Thus, the isolated MAECs were positive for the EC markers VE-Cadherin and vWF andcould form confluent monolayer with the typical EC cobblestone shape.Taken together, all these data suggest that the cells isolated from aortic rings areendothelial cells with some SMCs contamination.
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6.1.2. Adenoviral transfection of Rictor floxed MAECs leads to strong Rictor ablationIn order to generate endothelial cells lacking mTORC2 activity, MAECs were isolated frommice that have the 4th and 5th Rictor exons flanked by loxP sequences292. RICTOR is anessential component of the multi-complex that forms mTORC2 308. The excision of this genecould then be performed by infecting sub-confluent MAECs by adenovirus containing avector constitutively expressing the CRE-recombinase and green fluorescent protein(GFP). Green fluorescence, indicating a successful transfection was checked the day aftertransfection and both the cell groups (control with GFP alone and knockout with GFP andCRE-recombinase) resulted to be efficiently transfected, with a strong GFP expression(Figure 31).
Figure 31. GFP expression in transfected MAEC.Control cells on the left and knockout on the right. Pictures taken one day after transfection.
To verify whether Rictor was ablated in the transfected cells, Rictor mRNA was quantifiedby real-time PCR at different time points after transfection. In Figure 32, the chartindicates the Rictor mRNA levels in 3 different cell isolates three weeks after transfection.The amount of Rictor mRNA in the Ad-CRE-GFP treated cells resulted in being stronglyreduced compared to the control cells.
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Figure 32. Rictor mRNA levels of 3 different cell isolates.
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Rictor mRNA levels detected three weeks after adenoviral transfection by real-time PCR and normalized on theamount of Rictor mRNA present in the control cells of each cell isolate. The difference in Rictor expression wasstatistically significant (P value < 0.0001).
Also the Cre recombinase mRNA level was evaluated through real-time PCR quantification,in order to exclude any possible interference of this protein on the cell system, andtherefore being able to distinguish between the CRE-mediated and the RICTOR-mediatedeffects389. Cre recombinase message was intense three days after Ad-CRE-GFP transfection,but it decreased strongly three weeks after transfection ( Figure 33).
Figure 33. Cre recombinase mRNA levels.
Cre mRNA levels in Rictor control and knockout cells, were measured by real-time PCR 1 and 3 weeks afteradenoviral transfection.
Finally, Rictor knockout induction in MAECs five days after transfecting the cells with twodoses of Ad-CRE-GFP virus was proven on the protein level, by western blotting anddetection of RICTOR and CRE protein. CRE was strongly expressed only in the MAECstransfected with Ade-CRE-GFP adenovirus (both with a low and with a high dose ofadenovirus), where RICTOR levels where ablated ( Figure 34).
Figure 34. RICTOR and CRE protein
levels in MAECs.Immunoblots of cell lysates isolated fivedays after adenoviral transfection. Twodifferent volume of Ad-CRE-GFP viruswere used, obtaining the similar resultin terms of RICTOR ablation.
The adenoviral transfection then revealed itself to be a good method to generate, threeweeks after transfection, MAECs lacking of RICTOR displaying only a slight presence of theCRE recombinase.
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6.2. VEGFA as MAECs activatorWe detected a strong reduction of neovascularization in response to the potent angiogenicmolecule Fibroblast Growth Factor 2 (FGF2) in mice that lack endothelial RICTOR in vivo(see section “Results – Part A”). Angiogenesis is a highly regulated process in whichendothelial cells are activated by pro-angiogenic molecules such as Vascular EndothelialGrowth Factor A (VEGFA)390. Other groups demonstrated that FGF2 can induce VEGF ormodulate VEGF-elicited responses 375. We also showed by qRT-PCR that as consequence ofFGF2 stimulation there is an induction of Vegfa transcription (Figure 24B).As FGF2 induced VEGFA in our endothelial cells, we included VEGFA besides FGF2 asangiogenic stimulus to further assess potential mTORC2 dependent effectors of theangiogenic response in our endothelial cell isolates.
6.2.1. Vegfr1 (Flt-1), 2 (Flk-1/KDR) are not modulated by Rictor knockoutThe VEGFRs induce and are regulated by the Notch signaling pathway. This is particularlyimportant during sprouting angiogenesis when the differentiation of the endothelial cellsinto stalk and tip occurs391. The expression of different VEGFRs in the endothelium duringsprouting angiogenesis confers to the different endothelial characteristics: whereas the tipcells, expressing mostly VEGFR2, have a higher migratory ability and filopodia formation,the stalk cells, expressing mostly VEGFR1, can only follow the tip cells and proliferate 90, 213.We hypothesized that mTORC2 deficiency might lead to modulation of key angiogenicRTKs or angiogenic receptors and thereby might halt the angiogenic response in theendothelium. We focused on the receptors of the potent angiogenic molecule VEGFA.The modulation of these growth factors receptors was studied by real-time PCR in aconfluent monolayer of starved cells stimulated with 25 ng/ml of FGF2 or VEGFA for 1, 3or 6 hours.In addition to the results in the section “ Results – Part A” showing that the inductionof Vegfa, Vegfr1, sVegfr1 and Vegfr2 mRNA is not affected by mTORC2 ablation under FGF2stimulation (Figure 24B), we observed the same outcome using the pro-angiogenicmolecule VEGFA (
Figure 35).
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Figure 35. Vegfa and Vegfrs mRNA levels.Time course (1-6 hours) after FGF2 or VEGFA stimulation. Real-time PCR data, values normalized on thecontrol unstimulated.
Preliminary data indicated, after Rictor knockout, an increased expression of sVegfr1,whose codified protein, lacking of the transmembrane domain 392, is secreted and acts asVEGF scavenger105, fulfilling an anti-angiogenic function.However, since the induction of the sVegfr1 message was variable in the three cell isolates,we assessed sVEGFR1 protein levels in all control and Rictor knockout cells to betterunderstand whether mTORC2 can influence sVEGFR1 secretion,To do so, the supernatant from confluent MAECs stimulated for 24 hours with 25 ng/ml ofFGF2 or VEGFA was collected and analyzed by ELISA. The results showed that sVEGFR1protein levels in the supernatant were up-regulated after VEGFA and particularly FGF2stimulation however, its secretion was unaltered in mTORC2 knockout cells ( Figure 36).
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Figure 36. Soluble VEGFR1 protein levels.24 hours of incubation with FGF2 or VEGFA. ELISA data, values normalized on the control unstimulated.
6.2.2. Ang2 is up-regulated in starved Rictor knockout cellsTo assess whether the deficiency of mTORC2 might lead to endothelial cells with differenttip/stalk cell characteristics the induction of other genes involved in the Notch pathwaywas investigated. In parallel, we also considered the genes of the ANG-TIE axis which areinvolved in vessel stability and remodeling.The modulation of these genes was studied by real-time PCR in a confluent monolayer ofstarved cells stimulated with 25 ng/ml of FGF2 or VEGFA for 1, 3 or 6 hours. We foundthat Jagged1 and Ang2 gene expression was down-regulated in response to FGF2stimulation whereas VEGFA had no effect on their message. Rictor knockout did notfurther modulate Jagged1 expression. However Ang2 mRNA was significantly up-regulatedin the knockout cells when left unstimulated in the starving medium ( Figure 37). Theexpression of the gene transcripts Notch1, Dll4, Ang1 and Frizzled was not detectable atthe described conditions.
Figure 37. Jagged1 and Ang2 mRNA levels.
Jagged1
Fo
ld
 C
ha
ng
e
un
st
FG
F2
 1h
FG
F2
 3h
FG
F2
 6h un
st
VE
GF
A 
1h
VE
GF
A 
3h
VE
GF
A 
6h
0.0
0.5
1.0
1.5
2.0
Ang2
Fo
ld
 C
ha
ng
e
un
st
FG
F2
 1h
FG
F2
 3h
FG
F2
 6h un
st
VE
GF
A 
1h
VE
GF
A 
3h
VE
GF
A 
6h
0.0
0.5
1.0
1.5
2.0
Ctrl
KO
* *
76
Time course (1-6 hours) after FGF2 or VEGFA stimulation. Real-time PCR data, values normalized on thecontrol unstimulated (P value < 0.05).
6.3. Transcriptomic analysis of mTORC2-deficient MAECs
6.3.1. Gene array analysisAs we did not detect significant or wide-spread mTORC2-dependet modulation of genesassociated with angiogenesis by an ‘intelligent guess’ approach, we broadened ourinvestigations by analyzing the MAECs transcriptome by gene arrays. The MAECs, derivedfrom three different animals, were seeded and grown until confluence. When themonolayer was formed, the cells, starved for 24 hours, were stimulated with FGF2 orVEGFA at the concentration of 25 ng/ml. The genes transcription was investigated 3 and24 hours after stimulation to cover an acute and a chronic response to the growth factorsafter mTORC2 disruption. After incubating the cell culture with the GF, the RNA wasextracted, purified and its integrity was analyzed with the Bioanalyzer. The analysis ofrandomly selected samples showed RNA in an excellent quality, described by RIN (RNAIntegrity Number) factor between 9.8-10/10 and therefore suitable to perform the chiphybridization. A part of the RNA extracted was converted in cDNA and the presence of
Rictor and Cre in the transcriptome was assessed by real-time PCR. These samples, withconfirmed Rictor ablation and low Cre expression, were then further processed by theFunctional Genomics Center Zurich (FGCZ) where the Affymetrix work-flow wasperformed. The data generated in the FGCZ were then analyzed in detail in our laboratorywith the help of Dr. Christian Schaer by using the software JMP Genomics 7.0 (© SASInstitute Inc.). The samples were analyzed comparing the genes modulated in theknockout cells to the ones modulated in the controls, in absence of stimuli or after FGF2 orVEGFA incubation for 3 hours and 24 hours. Our analysis demonstrated that the biologicalvariability between the cell isolates from three different animals played a stronger rolethan the stimuli-induced changes used during the experiment. However, FGF2 was able tosignificantly induce or repress the transcription of several genes, both in 3 and in 24 hours(Figure 39). On the other hand, modulation of gene expression in MAECs stimulated withVEGFA was weak and did not display statistical significant compared to the unstimulatedcells in starving conditions. We therefore proceeded to assess whether the FGF2-inducedtranscriptome was modulated by mTORC2 deletion. We found that a rather small set ofgenes was differentially modulated by Rictor deletion in response to a 3 and 24 hourstimulation by FGF2 when compared to control cells. Interestingly the overlap betweenthe 3 hour set and the 24 hour set of genes was small, thus indicating that FGF-inducedgene expression changes over time ( Figure 38).
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Figure 38. Venn diagram.Chart summarizing differentially regulated genes in Rictor control and knockout MAECs in response to 3 and24 hour of stimulation by FGF2.
Figure 39. Volcano plots.These charts visualize changes between FGF2 and untreated control and Rictor knockout MAEC-derivedtranscripts. On the top the charts corresponding to the 3 hours incubation, on the bottom the charts of the 24hours stimulated samples. On the left, diagram of FGF2 modulated genes (up-regulated on the right and down-regulated on the left) in control cells. On the right, diagram of the genes modulated in Rictor knockout cells incomparison to the control cells in the same conditions. The red line represents the threshold of false detectionrate (FDR < 0.05). The vertical lines represent the border of the strongly modulated genes which are outside ofthe area generated by the lines.
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A pool of 28 genes involved in angiogenesis and differently expressed in knockout cellsunder FGF2 stimulation was identified ( Table 1). These genes resulted in being weaklyregulated as consequence of mTORC2 ablation but, however, this difference wasstatistically significant (FDR < 0.05)
Table 1. List of genes modulated in Rictor knockout MAECs (Transcriptome Analysis)
downregulated (not upregulated in FGF2 KO in 3 hours)
Affymetrix Identifier Gene name
17280310 ID2
17548973 Pten
17490628 FLT3l
17343299 Notch3
17400813 Notch2
17486967 Calmodulin (Calm3)
17287848 Smad5
17301502 α1B adrenergic receptor (Adra1a)
upregulated (not downregulated in FGF2 KO in 3 hours)
Affymetrix Identifier Gene name
17396240 MURF2 (Trim55)
17374488 Thrombospondin1 (Thbs1)
17221014 CD34
17396240  MURF2 (Trim55)
17234647 Integrin beta2 (Itgb2)
17356897 CALDAG-GEF1 (Rasgrp2)
downregulated (not upregulated in FGF2 KO in 24 hours)
Affymetrix Identifier Gene name
17379037 Plcg1
17343299 Notch3
17233347 Gja1 (Connexin34)
17392151 Jagged1 (Jag1)
17323909 Dvl3 (Disheveled)
17370977 Pkp4 (Plakophilin 4)
17368714 Hamartin (Tsc1)
17224211 Tensin1 (Tns1)
17228825 Klhl20 (kelch-like 20)
17366750 microRNA467a1
microRNA467a2
microRNA467a4
upregulated (not downregulated in FGF2 KO in 24 hours)
Affymetrix Identifier Gene name
17548559 Emp1 (epithelial membrane protein 1)
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17213213 Casp8 (Caspase 8)
17353923 Pcdh1 (Protocadherin 1)
6.3.2. Validation of the selected genesTo confirm the differences in gene expression elicited by Rictor deletion observed in thegene array analysis (Table 1), we proceeded to validate the results in time-courseexperiments. Control and Rictor knockout MAECs were stimulated with FGF2 or VEGFA for1, 3, 6 and 24 hours, RNA extracted, and qRT-PCR performed to detect the genes identifiedto be modulated in the gene array analysis. 16 genes out of 28 with CT value lower than 34were detectable in MAECs-derived cDNA. The real-time analysis showed that the inductionof Flt3L, Id2 and Notch3 was decreased after the treatment with FGF2 in a time frame of 6hours. The same stimulus up-regulated Thbs1 expression. Similarly; VEGFA could reducethe transcription of Id2 within 6 hours from the addition of the GF. However, none of thesetranscripts were differentially modulated by Rictor knockout at the time points and by thestimuli investigated (Figure 41 and Figure 41), suggesting that in these conditions, on thetranscription level, mTORC2 has no detectable impact on gene expression associated withangiogenesis in MAECs.
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Figure 40. Validation of the angiogenesis-related modulated genes (1-6 hours).Treatments with FGF2 or VEGFA were performed on a starved confluent MAEC monolayer of three differentcell isolates. Real-time PCR data, values normalized on the control unstimulated.
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Figure 41. Validation of the angiogenesis-related modulated genes (24 hours).Treatments with FGF2 or VEGFA were performed on a starved confluent MAEC monolayer of three differentcell isolates. Real-time PCR data, values normalized on the control unstimulated.
CASP8 (24 hours)
Fo
ld
 C
ha
ng
e
un
st
FG
F2
VE
GF
A
0
1
2
3
Emp1 (24 hours)
Fo
ld
 C
ha
ng
e
un
st
FG
F2
VE
GF
A
0.0
0.5
1.0
1.5
2.0
2.5
Klhl20 (24 hours)
Fo
ld
 C
ha
ng
e
un
st
FG
F2
VE
GF
A
0.0
0.5
1.0
1.5
PlCg (24 hours)
Fo
ld
 C
ha
ng
e
un
st
FG
F2
VE
GF
A
0.0
0.5
1.0
1.5
2.0
Dvl3 (24 hours)
Fo
ld
 C
ha
ng
e
un
st
FG
F2
VE
GF
A
0.0
0.5
1.0
1.5
2.0
Ctrl
KO
Gja1 (24 hours)
Fo
ld
 C
ha
ng
e
un
st
FG
F2
VE
GF
A
0.0
0.5
1.0
1.5
2.0
2.5
Ctrl
KO
Pkp4 (24 hours)
Fo
ld
 C
ha
ng
e
un
st
FG
F2
VE
GF
A
0.0
0.5
1.0
1.5
2.0
2.5
Ctrl
KO
TSC1 (24 hours)
Fo
ld
 C
ha
ng
e
un
st
FG
F2
VE
GF
A
0.0
0.5
1.0
1.5
2.0
Ctrl
KO
82
6.4. mTORC2 ablation leads to a higher Mcp-1 transcription induction in 24 hours of
FGF2 stimulationIn adulthood, angiogenesis can occur during wound healing 393 and in the femalereproductive system394, but also in pathological situations such as in tumor development 66or in inflammation60. Immune cells can secrete cytokines and GFs 395, 396 that stimulateangiogenesis. These cells can be recruited by the secretion of chemokines, such as MCP-1397, and adhere to the endothelium binding VCAM-1 and ICAM-1 398. To understandwhether the deficiency of mTORC2 in endothelial cells might influence the inflammatoryresponse, the expression of the inflammatory molecules Vcam-1, Icam-1 and Mcp-1 wasanalyzed in three different starved cell isolates. These confluent cells were stimulated for1, 3, 6 or 24 hours with 25 ng/ml of FGF2 or VEGFA. The RNA levels were measured byreal-time PCR and the ΔΔCT values were normalized on unstimulated control. The resultsshowed that FGF2 increased Vcam-1 and Mcp-1 transcription in 6 hours. VEGFA did notinduce the expression of the inflammatory molecules investigated. No differences,however, were noticed in the expression FGF2-induced Vcam-1 and Mcp-1 after 6 hours ofstimulation in knockout compared to control cells. Interestingly, within 24 hours, when
Mcp-1 induction decreased, cells stimulated with FGF2 and lacking mTORC2, showed a60% higher induction of this gene ( Figure 42). This result might point to a possible role ofmTORC2 in repressing chronic inflammation via Mcp-1.
Figure 42. Mcp1, Icam-1 and Vcam-1 mRNA expression.The mRNA levels were detected after 1, 3, 6 or 24 hours of FGF2 or VEGFA stimulation. Real time PCR data,values normalized on the control unstimulated. (24 hours of FGF2 stimulation data are also described in
Figure 26). (P value < 0.05).
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6.5. Secretome-analysis
6.5.1. mTORC2 knockout doesn’t affect the secretion of angiogenic molecules under
FGF2 stimulationOur in vivo data strongly suggest a role of mTORC2 in FGF2-driven angiogenesis (seesection “Results - Part A”). However, since we did not find significant mTORC2-dependentmodulation of gene expression on the transcriptional level ( Figure 41 and Figure 41), wehypothesized that changes may occur post-transcriptionally and alter protein levels as wedocumented for PKCα  whose transcription was not modulated whereas its protein levelsstrongly depended on RICTOR presence (Figure 24A and B).Endothelial cells can up-regulate the expression of angiogenic factors in hypoxicconditions84 or after growth factor stimulation97; moreover, we showed that FGF2 up-regulates the transcription of angiogenic molecules (for example Vegfa or sVegfr1, Figure
24B). We therefore investigated if angiogenic molecules are differentially secreted after
Rictor knockout in the supernatant of confluent starved MAECs stimulated for 24 hourswith 25 ng/ml of FGF2 or VEGFA.The supernatants, obtained from the cell culture of three different cell isolates, wereincubated on a membrane anchored with antibodies targeting 53 different moleculesinvolved in angiogenesis (see section 8.21). The amount of the proteins underinvestigation was detected by a chemiluminescent reaction ( Figure 43). Densitometricanalysis was performed using ImageJ.
Figure 43. Angiogenic ligand protein array.Each dot doublet represents a secreted molecule which impacts angiogenesis. The two membranes wereincubated with the supernatants for 24 hours with VEGFA. Arrows indicate dot blots corresponding to the HGFprotein.
9 of the 53 ligands were detectable in the supernatants of all the three cell isolates.In response to FGF2 or in unstimulated conditions, none of the ligands assessed resulted inbeing differentially secreted in cells deficient in mTORC2 ( Figure 44).
Control, VEGF Knockout, VEGF
84
6.5.2. mTORC2 regulates VEGFA-induced HGF secretionIn response to VEGFA, we could identify one protein whose secretion is influenced by thepresence of the mTORC2 complex. We found indeed that the Hepatocyte Growth Factor(HGF) protein secreted levels were decreased in Rictor knockout cells (Figure 44). Thisdifference corresponding to ca. 50% down-regulation was statistically significant (P <0.05). HGF is a potent mesenchyme-derived cytokine that can stimulate EC proliferation,growth and motility in vitro76 whereas, in vivo, it is a potent angiogenic factor76, involved inwound healing132 and in organ development130. HGF is also found to be overexpressed ininvasive human cancers, such as breast cancer 133 where it can promote the formation ofcapillary-like tubes.
Figure 44. Angiogenic ligands secreted in the culture supernatants.The secreted proteins from three different cell isolates were collected after 24 hours of stimulation with FGF2or VEGFA. Values reported as fold change in comparison to the control unstimulated.  (P value < 0.05).
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6.6. mTORC2, eNOS and nitric oxide production in MAECsNitric oxide (NO) is a central molecule to enable angiogenesis. NO stimulates endothelialmigration172, survival174 and proliferation173. VEGF-dependent effects in angiogenesisrequire NO176 which is up-regulated, along with endothelial-specific NO synthase (eNOS)107. NO also up-regulates FGF2 173 and, in rat SMC, VEGF synthesis182. In endothelial cells,PKCα354 and AKT325 can activate eNOS by phosphorylating its Ser 1179 residue andconsequently lead to NO production. Our previous in vitro analysis showed that total PKCαprotein levels are strongly reduced as well as the levels of AKT phosphorylated on Ser 473residue after mTORC2 disruption in primary cultures of MAECs 333 (see also Figure 24A).We therefore aimed at elucidating, whether mTORC2 can influence NO production inendothelial cells. We first attempted to determine the mRNA and protein levels of eNOS byreal-time PCR and immunoblots however, they were undetectable in confluent MAECsgrowing in full medium or in starving conditions. We therefore decided to quantify thenitrites accumulating in our MAECs supernatants (consequence of NO oxidation) asindirect measure of NO production. MAECs were seeded in 6-well plates and grown untilconfluence. After starvation, the monolayer was stimulated for 20 minutes, 24 or 48 hourswith the angiogenic molecules FGF2 (25 ng/ml), VEGFA (25 ng/ml) and with FCS (10%),ACh (10 µM) or TNFα (10 ng/ml), used as controls. The supernatant was then collectedand the levels of nitrites measured by spectrophotometry after the Griess reaction (seesection 8.22). After 20 minutes, we could observe an induction in nitrite production inMAECs stimulated with FGF2, VEGFA and TNFα ( Figure 45). However, though nitritelevels appeared to be lower in supernatants of Rictor knockout cells, no statisticaldifference was computed comparing values from control to Rictor knockout cells. After 24hours of ACh incubation, an induction in nitrite levels was observed in the control cellsupernatant whereas knockout cell supernatant displayed a clearly lower and statisticallysignificant (P<0.05) amount of nitrites ( Figure 45). Based on these results, we may notassume, that FGF2-induced NO production is essentially decreased by mTORC2 deficiency.We have therefore to exclude the possibility for the time being, that FGF2-inducedangiogenesis in vivo might involve the mTORC2-NO axis. However, the significant decreasein NO production in response to ACh after Rictor knockout might point to potentialdeficiencies in vasorelaxation.
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Figure 45. Nitrites amount in the MAECs supernatant, measured by Griess reaction.The three cell isolates used in the experiments were either unstimulated or treated with FGF2, VEGFA, FCS,Ach or TNFα for 20 minutes, 24 or 48 hours. Values normalized on the control unstimulated. (P value < 0.05).
6.7. mTORC2 has no impact on actin cytoskeleton rearrangementmTORC2 and PKCα strongly influence the cytoskeletal organization 312, 348. Thecytoskeleton plays an important role in many cellular processes such as cell adhesion andmigration399. The migratory ability is an essential feature of endothelial cells duringangiogenesis400, 401. We therefore analyzed whether Rictor knockout cells might show adifferent organization of actin fibers, an important component of the cytoskeleton. Inparticular, we focused on potential defects in F-actin polymerization and altered cell shapein Rictor knockout cells312, 348, 349. MAECs were seeded in culture slides, starved andstimulated with FGF2 or VEGFA at the concentration of 25 ng/ml for 1, 3 or 6 hours. Thecells were then permeabilized and stained with fluorescent-labeled Phalloidin andphotographed under a fluorescent microscope. Unstimulated cells showed a similar actindistribution, without the formation of extensive actin filaments both in knockout andcontrol cells. One hour after FGF2 or VEGFA stimulation, the presence of actin fibers wasnoticeable both in control and in knockout cells. The distribution and the edge of the actinfilaments were comparable in control and Rictor knockout cells (Figure 46). Also the cellshape was not affected by the ablation of mTORC2.
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Figure 46. Immunofluorescent stain of MAEC actin cytoskeleton.MAECs, control and Rictor knockout, incubated with FGF2 or VEGFA for one hour and afterwards stained usingPhalloidin (orange) binding the acting filaments and DAPI (pink) detecting the nuclei.
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7.     DISCUSSION
In this study we (A) deleted Rictor in the endothelium to study the general requirement ofendothelial mTORC2 during embryonic and adolescent development and (B) used Rictorknockout in endothelial cells to elucidate potential molecular mechanisms.
7.1. Embryonal developmentOur analysis of embryonic development using constitutive and inducible VE-Cadherin-CRE-specific Rictor knockout confirmed that homozygous Rictor deletion in endothelialcells is almost completely lethal and results in embryonic death around E12. Guertin et al.proposed that vascular defects may contribute to the lethality of whole-body Rictorknockout embryos on E10.5328. Furthermore, Wang et al. demonstrated that thehomozygous and Tie2-CRE-driven Rictor knockout is embryonically lethal372. However,other than reductions in peripheral vascularization, we did not detect gross abnormalitiesof the normal vascular plexi on E10.5 ( Figure 20 and Figure 21). Surviving embryosaround this time frame showed rather distinct deficits in vascularization and weregrowth-retarded. The vascular embryonic phenotype strongly resembled the one found intotal mTORC2-deficient mice lacking Rictor or mLST8, which are both essential mTORC2components310, 328. Therefore, we suggest that the critical embryonic function of mTORC2at midgestation originates in the endothelium. Specifically, we detected a delayedossification of the vertebrae, toes, and fingers ( Figure 21). Delayed ossification mayexplain growth retardation but may not categorically explain embryonic lethality of
RictoriΔec in the confined midgestational timeframe. Thus, other essential functions that areregulated by mTORC2 during this short period in midgestation are probable and may alsoaccount for lethality.Many signaling pathways that are involved in early embryonic development are alsorecapitulated during tumorigenesis402. As we found that endothelial mTORC2 wasrequired during a confined, midgestational timeframe but had no apparent influence onviability before midgestation (E8.5), beyond midgestation (E14.5), physiological vasculardevelopment, vascular maintenance and growth from adolescence into adulthood, wehypothesized that endothelial Rictor might promote only ‘aberrant’ endothelial phenotypemodulation such as in tumor angiogenesis or during a transition to an invasivemesenchymal phenotype. Guertin et al. demonstrated that  Rictor has no significant role byitself in maintaining the integrity of a normal prostate epithelium in vivo but requires
Rictor to be transformed into an invasive, malignant phenotype by Pten deletion, which
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results in strong PI3K activation 403. Similarly, Drosophila embryos lacking mTORC2activity are viable and display only minor growth defects 404 403. However, PTEN loss-induced tissue overgrowth in the Drosophila eye requires dTORC2 404.
7.2. FGF2-induced capillary remodeling and neo-angiogenesis in vivoWe found that particularly FGF2 and not VEGFA depended on the mTORC2 signaling hubto establish a capillary-like endothelial network on matrigel substrate when we testedthese PI3K-activating angiogenic molecules in vitro. We found that FGF2 elicited a strongand fast increase in the diameter of existing skin capillaries in the dorsal skinfold chamberafter two days of stimulation in both control and RictoriΔec mice (Figure 25). Over a periodof 7 days, FGF2 induced the progressive and extensive remodeling of vessel structurescharacterized by heterogeneous and larger diameter sizes that also included largerarterioles and a tortuous vascular bed in control mice. RictoriΔec mice however, could notmaintain heterogeneous capillary size remodeling beyond day 2 of FGF2 exposure andreturned to ‘normalized’ vascular features with homogeneously and smaller sizedcapillary diameters and parallel-oriented capillaries. Tortuous and dilated capillaries arealso found in vascularized tumors. Tumor blood vessels furthermore display hyper-permeability, and do not mature into functional vasculature 405, 406. However, we could notdetect fewer leakage points in FGF2-stimulated skin capillaries RictoriΔec in preliminaryinvestigations.However, the supply of FGF2 to the skin muscle over a period of seven days was limited bythe volume of the matrigel carrier (16 µl) and may not have provided saturated FGF2-stimulation at all times. We therefore continued our investigations using the matrigel plugassay carrying pathologically high doses of FGF2 in a volume of 200 µl to induce aberrant,leaky and tumor-like angiogenesis as reported before 382. Indeed, we observed a dense,heterogeneous neo-vasculature with several patches of hemorrhage that formed after 7days in control mice (Figure 26). Endothelial Rictor knockout strongly and significantlyreduced FGF2-mediated neo-vessel ingrowth, and capillaries remained homogenouslysmall with no microscopic signs of leakage. Our study thus demonstrates that endothelialmTORC2 acted as a central signaling hub for FGF2-induced persistent capillary diameterincreases and remodeling into heterogeneous capillary structures and formation of aleaky, tumor-like neo-vasculature in the adult mouse.
7.3. FGF2 in angiogenesis and osteogenesisFGF2, which is not secreted through vesicular pathways, can be exported from cells withunique extrusion pathways or large amounts can be released upon cell death 407,382. FGF2
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has been selectively determined as a crucial tumorigenic cytokine in prostate cancers inwhich both FGF2 and FGF2 receptor subtypes are co-expressed 408 409. In addition manyother tumor types express FGF2/FGFRs at high levels 410, 411, 412-414, 382. On the other hand,fibroblast growth factors are involved in the formation of skeletal elements within thedeveloping limb415-417. Several FGFs are expressed in developing endochondral bone. FGF2was the first FGF ligand to be isolated from growth plate chondrocytes 52. FGF2 expressionhas also been observed in periosteal cells and in osteoblasts 51, 418. Targeted deletion ofFGF2 causes a relatively subtle defect in osteoblastogenesis, leading to decreased bonegrowth and bone density419, 51.
7.4. FGF2- and VEGFA-induced signaling via mTORC2 downstream targets AKT and
PKCαMany researchers have demonstrated that FGF2 induces AKT phosphorylation on Ser 473 inendothelial cells420. In other reports, mTORC2 contributed to AKT stability and activity 333,334. Here, we show that mTORC2 is required for AKT phosphorylation on the Ser 473 residueand that this phosphorylation is increased in a FGF2 dose dependent manner ( Figure
24A). In our system, we could also observe that mTORC2 is required for PKCαstabilization, as demonstrated previously 313, 333, 334 (Figure 24A). Therefore the impact ofmTORC2 on angiogenesis, observed in our experiments in vivo may be explained with adifferent AKT or PKCα activity within the endothelial cells. These two kinases wereinfluence different phenomena implicated in angiogenesis, such as cell proliferation,migration, differentiation or network formation; perhaps by regulating FoxOs activity 328,329 or other downstream factors62, 92, 315-318, 352, 353 .Not all of these cellular responses, however, were affected by a different activation orpresence of the two kinases AKT and PKCα in our cell culture experiments: FGF2-drivenproliferation and migration were not differently regulated in mTORC2 knockout cells(Figure 24B). VEGFA-driven proliferation instead, decreased as consequence of Rictorknockout (Figure S5). Also the ability of endothelial cells to establish a capillary-likenetwork in vitro under FGF2 stimulation was impaired in Rictor knockout cells, but thesame effect was not detected during VEGFA stimulation (Figure 23). Thus, the different in
vivo and in vitro phenotypes observed in mTORC2 knockout endothelial cells might be dueto a post-transcriptional regulation of AKT and PKCα.AKT and PKCα can activate eNOS 325, 336, 354. Since eNOS function consists in producing NO,an instable molecule which is implicated in vasodilation 169, 170 and angiogenesis78, 171-176,we decided to investigate the levels of NO in our cell culture system and quantify thenitrites, a product originated by the NO oxidation in the cell supernatants 156, 190. In these
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experiments, VEGFA robustly stimulated nitrite production but, however, mTORC2absence did not alter the nitrite levels (Figure 45). On the other hand, starved or FGF2-stimulated mTORC2 knockout cells produced lower amounts of nitrites then the controlcells, but this difference didn’t result in being statistically significant ( Figure 45). Thedifference between control and Rictor knockout cells in nitrite production after 24 hoursof ACh stimulation, however, was statistically significant. Thus, mTORC2 might be involvedin vaso-relaxation via ACh-mediated NO/nitrite production ( Figure 45). In future, it mightbe interesting to investigate the role of mTORC2 in vascular function in detail tounderstand whether AKT and PKCα are directly involved in this phenomenon. Moreover,in order to obtain more precise data regarding nitric oxide production, instrumentsdirectly measuring NO, such as chemiluminescence analyzer or amperometric NO sensors,could be used.
7.5. A hypothetical VEGFA-mTORC2-HGF loop?During the analysis, of the angiogenic factors released in the culture supernatants, a highvariability between the isolates was observed: proteins strongly secreted in one isolateresulted to be absent in the other (see section 7.9.1). Despite that, the secretion of thehepatocyte growth factor (HGF) was quantifiable in all the isolates ( Figure 44). In theknockout MAEC monolayer, VEGFA-induced secretion of HGF was strongly reduced. HGF isa growth factor expressed in malignancies such as breast cancer 133, 421 that can stimulateangiogenesis by increasing endothelial cell growth and mobility 76, 137. VEGF is also one ofthe main pro-angiogenic factors frequently expressed in tumors. A furthercharacterization of the molecular interaction connecting HGF secretion to VEGFAstimulation via mTORC2 might be of clinical interest since, as demonstrated earlier,blocking HGF in mouse xenografts leads to a decreased tumor invasiveness and growth 421.Therefore, using compounds inhibiting both mTORC2 and HGF might lead to a strongereffect.Additionally, it was observed that VEGFA and HGF can contribute synergistically toendothelial cell proliferation and migration137. This observation is in line with our resultsof the VEGFA-induced proliferation assay performed ( Figure S5) where the controlendothelial cells had a higher proliferation rate compared to Rictor knockout cells. Further
in vitro works may confirm the involvement of endothelial mTORC2 in HGF secretionunder VEGFA stimulation.
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7.6. mTORC2 is involved in Ang2 expression but not in Vegfrs mRNA modulationThe Notch signaling pathway modulates the expression of VEGF receptors in endothelialcells. This pathway is involved in differentiating the endothelial cells into tip and stalkphenotypes that perform individual roles in sprouting angiogenesis 213. VEGFA was shownto up-regulate Vegfr1 and Vegfr2 transcription in endothelial cells 422-424. In our system wefound that VEGFA up-regulated sVEGFR1 secretion ( Figure 35 and Figure 36). On theother hand, it is shown that FGF up-regulates Vegfr2 mRNA expression in vivo425. Again, wefound that FGF2 strongly increased Vegfr1 and sVegfr1 transcription whereas it reduced
Vegfr2 ones (Figure 24B). FGF2 was also observed to induce sVEGFR1 secretion ( Figure
36). In all of these processes, however, mTORC2 was never involved and therefore wesuggest that mTORC2 doesn’t contribute in endothelial tip/stalk cell differentiation.FGF2 and VEGFA increase Ang2 expression in endothelial cells426, 427. In our cell culturesystem Ang2 expression strongly decreased after FGF2 stimulation or remained constantafter adding VEGFA (Figure 37). Interestingly, Rictor knockout cells compared to controlsinduced higher levels of Ang2 in unstimulated conditions (Figure 37). ANG2 is particularlyexpressed in the remodeling endothelium but it was suggested that endothelial cellsexposed to this protein in absence of VEGF can undergo in apoptosis 235. Thus,hypothetically, mTORC2 could be involved in the transition from a quiescent endotheliumtowards a remodeling one or drive towards apoptosis when survival signals are missing.
7.7. Endothelial RICTOR and inflammatory moleculesTranscripts codifying for the inflammation molecules Icam-1 and Vcam-1 were analyzed.The expression of these molecules was not affected by the Rictor knockout (Figure 42).However, the expression of Mcp-1 mRNA remained significantly higher in Rictor knockoutcells after 24 hours of FGF2 stimulation ( Figure 42). MCP-1 was shown to enhanceendothelial cell migration during wound repair 428. During the time course in our woundhealing assay, however, we couldn’t observe any vantage in motility of the mTORC2knockout cells stimulated with FGF2 ( Figure 24D).MCP-1 is also involved in monocytes recruitment 397. Interestingly, we observed a small,though statistically insignificant trend, towards denser packed stromal halo in FGF2-containing matrigel plugs from Rictor knockout animals and consecutively higher CD68 +macrophages (Figure 26). Thus, hypothetically, mTORC2 might play a role in chronicinflammation, perhaps by inhibiting the monocytes recruitment to the endothelium.Indeed, related research from our unit demonstrated that ablation of Rictor in adipocyteslead to increased expression of inflammatory cytokines 429. Thus, decreased mTORC2activity turned on a cascade of inflammatory pathways.
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Still, a possible higher Mcp-1 induction in Rictor knockout MAECs is likely unrelated to ourmain findings of a crucial requirement of the FGF2-RICTOR axis in capillary remodelingand extensive angiogenesis (Figure 25 and Figure 26) since higher amount of MCP-1released from the endothelium should lead to a higher amount of monocytes recruited,cells which have the ability to secrete growth factors (e.g. VEGF) with pro-angiogeniceffects.The amount of MCP-1 protein was also studied during the secretome analysis, but itspresence in the medium was not affected by the absence of mTORC2 after 24 hours ofstimulation (Figure 44). Further investigations on MCP-1 protein levels are thereforerequired in order to understand whether the difference observed on the RNA level is alsoreproduced on the protein one.
7.8. A potential role for RICTOR in endothelial to mesenchymal transition?Interestingly we found that quiescent and starved MEAC expressed low levels of RICTORin control cells. High doses of FGF2 however induced RICTOR protein in correlation withhigh phosphorylation of AKT on Ser 473 (Figure 24A). Comparable findings were reportedduring the epithelial to mesenchymal transition (EMT). Transforming growth factor (TGF-
β), a strong inducer of EMT, increased RICTOR protein and thereby formation of mTORC2in mouse mammary gland epithelial cells 430. Without RICTOR, the epithelial cells arrestedin an intermediate stage between epithelial and mesenchymal without displaying a motileand invasive phenotype430. Interestingly, TGF-β1 treatment also induces an interactionbetween RICTOR and integrin-linked kinase (ILK) and promotes ILK-dependent EMT. Thiscomplex was detected in cancer but not in normal cell types 431 and overlaps with mTORC2in the function as AKT Ser473 kinase432. Thus, RICTOR could promote EMT by formingdifferent complexes.In parallel to EMT, endothelial to mesenchymal transition (EndoMT) can be induced bytransforming growth factor (TGF-β) 433. EndoMT is a newly recognized type of cellulartrans-differentiation that participates in development, but also in pathological conditionssuch as cancer and fibrosis 433-435. New studies have shown that EndoMT represents adedifferentiation of endothelial cells to a stem cell phenotype, which can re-differentiateinto bone or cartilage cells435, 433, 436. Thus, hypothetically, endothelial RICTOR may berequired during midgestation to promote the transition of endothelial cells to amesenchymal, osteogenic phenotype to promote FGF2-directed ossification of limbs andvertebrae. During further development through normal adolescence where mostvasculature is quiescent, with only 0.01% of endothelial cells undergoing division 437,endothelial Rictor knockout may represent the characteristics of an unchallenged
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quiescent endothelial monolayer with low RICTOR expression and AKT activity. Recentstudies suggest, during angiogenic sprouting, endothelial cells express many of EndoMT-driving genes and break down basement membrane. However, they retain intercellularjunctions and migrate as a connected train of cells 434. This process has been termed apartial EndoMT434. The permanently activated phenotype of tumor vasculature may wellreflect the chronic activation of the EndoMT process, driven by persistent angiogeniccascades, leading to excessive sprouting and a failure to settle back into the mature, stablephenotype434. Thus, hypothetically, endothelial mTORC2, assembled through increasedFGF2-increased RICTOR presence may promote neovascularization by a sustained partialEndoMT.
7.9. Outlook and technical considerationsIn parallel to our main findings, I kept looking for a potential molecular mechanism inorder to explain our in vivo phenotypes (section “ Results – Part B”). I thereforeinvestigated on the transcription level which genes are modulated after mTORC2 ablationunder FGF2 or VEGFA stimulation. I used gene arrays to analyze the general transcriptomein MAECs after Rictor knockout and I also investigated on the proteins, involved inangiogenesis, secreted by MAECs after Rictor knockout by using antibody arrays.However, these high-throughput analyses did not reveal any gene or protein regulatedupon FGF2 administration in a Rictor-dependent way in MAECs. Thus, no furthermolecular explanation for our in vivo phenotype could be elucidated using MAECs in vitro.
7.9.1. Endothelial cells characterization and variabilityThe approach used to isolate the MAECs is a technique already described in literature andfrequently used in our group to isolate endothelial cells from murine aortas. During thisprocedure, under constant stimulation of growth factors (FGF2, VEGFA, ECGS), theendothelial cells sprout out of aortic rings previously cleaned form the perivascular tissue.Three different cell isolates (ISO1-2-3) characterized by the typical endothelialcobblestone cell shape could be obtained. To assess whether these cells were indeedendothelial cells, the most important markers for endothelial cells were analyzed by real-time PCR. Cd31 mRNA and its smaller spliced variant, both codifying for the membraneprotein expressed mainly on the EC surface 26, 386, 438, were not expressed in our endothelialisolates. The same outcome was given by the analysis of the other marker Tie2 andpartially by Cd34. However, the three isolates exhibited the typical endothelial cell shape,expressed the endothelial marker VE-Cadherin and were positive for endothelial markervWF. Thus, some classical markers for the endothelium could not be maintained in
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cultured cells, whereas others were expressed and the morphology homogeneity exhibitedan endothelial phenotype.The main issue faced by using these cells was the high biological variability displayed bythese isolates which perhaps contributed to hide most of the differences generated afterknocking out Rictor in the high throughput  experiments (transcriptome and secretomeanalysis).The source of this biological variability might be due to the MAECs isolation procedure, aprocess that was already documented to alter the normal endothelial cells behavior andgene expression observed in vivo, possibly due to the change of the microenvironment orto epigenetic mutations387, 388. Moreover, another source of variability might be a possibledifferent doubling time of the cell isolates. The cells sprouting out the aortic rings needdifferential time for outgrowth. Some rings, also belonging to the same aorta, led to a quickendothelial cells growth, characterized by many sprouts outgrowing from the ring. Forother rings, the time required from the endothelial sprouts to reach the well edge, wasmuch longer. During this period, indeed, the cells undergo to a different number ofdivisions, which may contribute to increase the variability from isolate to isolate.Another source of variability might be the presence of contaminating cells sprouting outfrom the aortic rings together with the endothelial cells since not all of the perivascularand mural cells (e.g. SMCs, Figure 30) can be easily removed by hand.In order to obtain isolates of purer quality, more trials were performed, either placing theaortic rings in hypoxic environment or incubating them with different growth factors andfor different time periods, but only co-cultures, mostly constituted by SMCs, could beobtained. We also tried the MACS and FACS-sorting techniques to isolate either aortic orlungs endothelial cells, but the main issues, faced during these strategies, was the lowpercentage of surviving endothelial cells after 2 or 3 passages in culture. This problemmight have been avoided by immortalizing the sorted cells but it would have altered theintracellular molecular pathways. Again, another opportunity to obtain isolates of purerquality might be to use wild-type ECs (not Rictor floxed) available in commerce and toinduce the knockout of the gene of interest with different strategies (e.g. siRNAs, shRNAs,PNAs or other techniques) whose efficacy may not be as high as in our adenoviral system.
7.9.2. Hypoxia as a natural angiogenic stimulusBased on the cellular assays which demonstrated in normoxia that the ablation of Rictorled to in vitro phenotypes in our MAEC ( Figure 23 and Figure S5); we investigated onpotentially modulated molecular pathways under normoxic conditions. However, sinceangiogenesis is strongly induced in hypoxic conditions, in future it might be more fruitful
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to use hypoxia as primary stimulus for the activation of the endothelial cells; or also tocombine it with growth factor stimulation (e.g. FGF2, VEGFA, PDGFB). In this way, theactivation of the endothelial cells might be more pronounced and the existence of possiblemolecular pathways modulated after mTORC2 disruption may emerge.
7.10 ConclusionIn conclusion, our data suggest that the endothelial FGF2-RICTOR axis is not requiredduring endothelial quiescence or moderate capillary remodeling, but it is crucial formidgestational development and sustained and extensive neovascularization in the adult.Moreover, on the molecular level, we observed that endothelial mTORC2 is involved in thesecretion of HGF as consequence of VEGFA stimulation and it also modulates Ang2 and
Mcp-1 transcription respectively in starved and in FGF2-stimulated endotheliummonolayer. Furthermore, we hypothesize that mTORC2 might also be implicated invasodilation since its absence in MAECs led to a reduced amount of nitrites producedunder ACh stimulation. Again, we could show that RICTOR is required for PKCα stabilityand AKT activation but, however, in our system, we could not find molecular pathwaysinvolved in angiogenesis to be affected by Rictor ablation.Therefore, further studies are needed to uncover the exact and maybe related molecularnature that enables endothelial mTORC2/RICTOR to promote both ossification in theembryo and extensive and aberrant FGF2-dependent angiogenesis in the adult.Other directions for future investigations might regard the possible role played byendothelial mTORC2 in several different processes: NO-mediated vasorelaxation, VEGFA-promoted HGF secretion, MCP-1-induced inflammation or ANG2-driven vascularremodeling.
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8.     MATERIALS AND METHODS
8.1. Animal proceduresMice with floxed Rictor exons292, 439 were crossed with mice that express tamoxifeninducible Cre-ERT2 under the control of the endothelium-specific VE-cadherin promoter(VECad-Cre-ERT2)369 (kind gift of  Dr. Iruela-Arispe, Department of Molecular, Cell &Developmental Biology, UCLA, USA) both on  a congenic C57Bl/6J background. Offspringwere genotyped for CRE-recombinase, Rictorfloxed and Rictorwt alleles using qPCR. Briefly,DNA was isolated from ear biopsies and amplified by qPCR with the following primer pairs(5’-3’): Forward: GCG GTC TGG CAG TAA AAA CTA TC; Reverse: GTG AAA CAG CAT TGCTGT CAC TT. The mice were bred, housed and handled according to the local animal ethicscommittee. All procedures with mice were approved by the Veterinary Office of the Cantonof Zürich, Switzerland under licenses 77/2009 and 179/2012.
8.2. Whole mount embryo stainingEmbryos were stained with an antibody against endomucin according to Vieira et al. 440. Inbrief, embryos were fixed for two hours on ice with PBS containing 4% PFA. After threewashing steps with PBS containing 0.1% Triton X-100 and blocking of unspecific bindingsites by incubation with PBS containing 10% FCS and 0.1% Triton X-100 for 30 minutes atroom temperature, embryos were incubated with rat monoclonal antibody againstendomucin (1:100, Santa Cruz Biotechnology) dissolved in PBS over night at 4°C followedby five washing steps with PBS at room temperature. After incubation with secondaryantibody anti-rat Alexa Fluor-555 (1:200, Molecular Probes) over night at 4°C and threefurther washing steps with PBS, embryos were mounted and analyzed by laser scanningconfocal microscopy (SP5; Leica, Wetzlar, Germany). Staining of whole embryos for LacZwas as described previously441.
8.3 Alizarin Red and Alcian Blue stainingsFor skeletal staining, embryos were fixed in 95% ethanol for more than four days, afterremoval of fat and connective tissue, incubated in acetone for one day and stained with0.15% alcian blue 8GS (Sigma-Aldrich)/ 0.05% alicarin red S (Sigma-Aldrich)/ 5% aceticacid in 70% ethanol at 37°C for two days. After bleaching in 1% KOH for 12 to 48 hoursembryos were de-stained with graded washes of glycerin (20% glycerin in 1% KOH, 50%
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glycerin in 1% KOH and 80% KOH in 1% glycerin). Embryos were stored in 100%glycerin.
8.4. Histological analysisEmbryos and dissected organs from adult mice were fixed in 4% PFA in PBS, transferredto ethanol and embedded in paraffin. Longitudinally-sectioned paraffin-embeddedembryos and organs were stained with haematoxylin and eosin. For CD31 stainingparaffin sections were stained as described previously 442. Sections from dorsal chamberswere de-paraffinized and rehydrated in xylene and isopropanol and antigens retrieved byboiling in trisodium citrate. Rabbit polyclonal anti-mouse Estrogen Receptor α antibody(Millipore) was used for detection and visualized by secondary goat anti-rabbit Alexa-Fluor 555 (Invitrogen) using microscopes and cameras from Zeiss and Olympus.
8.5. Determination of Rictor mRNA expression levels in endothelial cells from
thoracic aorta
Rictor deletion was induced in VECad-CreERT2; Rictorfloxed/floxed  mice at an age of fourweeks with five consecutive intraperitoneal tamoxifen (Tx) injections according to theprotocol of Monvoisin et al.369. (2 mg Tx /ml dissolved in corn oil at a concentration of 80mg/kg bodyweight, T5648, Sigma-Aldrich). Littermate control mice were injected withcorn oil alone. This injection protocol was used for all experiments in this study.Aortae were excised from 6 month old Tx-injected (RictoriΔec) and control mice (Ctrl),cleaned from adhering tissue and opened longitudinally. Endothelial cells were carefullyscraped directly in RLT buffer (Qiagen) and RNA was extracted using the RNAeasy microkit (Qiagen) according to the recommendations of the manufacturer. Equal amounts ofRNA were transcribed to cDNA by WT (Whole Transcript)-Ovation™ Pico RNAAmplification System (NuGEN). Quantitative real-time PCR was performed using a SYBRgreen-based standard protocol. Primer list is shown in section ‘Real-time quantitativereverse transcription polymerase chain reaction’. Specificity of the primers was tested bymelt curve and agarose gel analysis and sequencing. Relative expression levels werecalculated using the comparative ΔCt method 443
8.6. Isolation of endothelial cellsMouse aortic endothelial cells (MAECs) were isolated from aortae of 8-10 weeks old Rictorfloxed (exons 4 and 5) C57BL/6 mice 444, 364. Briefly, fibrin gels were prepared by mixing 3mg / ml of fibrinogen with serum-free DMEM complemented with non-essential amino
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acids, Sodium Pyruvate, Pen-Strep and thrombin on ice. 24-well plates were coated withthe prepared fibrin gel allowed to polymerize at 37 oC. The excised aorta was cleaned, cutin small rings and placed on top of the gel and overlaid by fibrin gel. After gel hadpolymerized pre-warmed growth media (serum-free DMEM that contained 10 % FCS, 200
μg / ml of ECGS, 10 ng/ml of FGF2 and 0.1 IE /ml of heparin) was loaded to the wells. Toprotect the fibrin gel from degradation, 300 μg / ml of ε-amino caproic acid (Sigma A-7824) diluted in PBS was added to all wells every other day. After 10 days of culturing,capillary-like sprouts were observed under the microscope. The outgrown cells wereharvested by pipetting up and down the fibrin gel. The gel-cell mixture was transferred toa six-well plate which had previously been coated with 0.1% gelatin gold, and 1 ml / wellof growth media w/o heparin was added. The next day, cells were washed once with warmPBS and new EC growth media was added. Confluent cells were split 1:2 by trypsinizationusing TrypLETM-Express and characterized.
8.7. Endothelial cells characterizationThe characterization of the isolated cells was performed by macroscopic observation ofthe cell shape, analysis of the transcriptome and staining of surface markers. Cd31, Cd34,VE-Cadherin and Sm22α expression was analyzed in confluent monolayer of cells growingin full medium, using the primers listed in the Table 2. The expression of these genes inthe isolated cells was compared to their expression in SMC, adipocytes, fibroblasts, aorticarch, and other MAECs (Cell Biologics, #C57-6052). The presence of the endothelialmarker von Willebrand Factor was detected by immune fluorescent stain using vonWillebrand Factor antibody (vWF, LabForce AG).
8.8. Cell culture and treatmentsFor all the experiments using MAECs, cell culture dishes were coated with 0.1% gelatingold (Carl Roth GmbH, #4274.1) for 20 minutes at 37°C. MAECs were maintained in DMEM(Biochrom, #FG435), complemented with 10%, 1% or 0.5% (complete or starvationmediums) FCS (Biochrom, #S0615), 1% sodium pyruvate (GIBCO, #15140), 1% non-essential amino acids (GIBCO, #11140) and 1% penicillin-streptomycin (GIBCO, #15140).Stimulation with the growth factors FGF2 (R&D Systems, #3139-FB/CF) or VEGFA (R&DSystems, #493-MV/CF) always included coupling with heparin (Braun, #3511014) at afixed ratio (1 IU heparin per 1.5 μg/ml GF) one hour before at room temperature. Othermolecules used in cell treatments were ACh (Sigma, #A6625), TNFα (Sigma, #T7539) andinsulin (Sigma, #I0516).
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8.9. Generation of Rictor KO cells
Rictor knockout was induced by adenoviral transfection of CRE-Recombinase on Rictorfloxed MAEC. 2.5x105 Rictor floxed MAECs were seeded on a 6 cm culture dish. The nextday, the media was removed and a virus (100 MOI) that contained either Ade-CRE-GFP(Vector Biolabs 1045) or Ade-CMV-GFP (Vector Biolabs 1060) was added in 1 ml ofgrowth media to the cells. After 7 hours, the media was removed, replaced by 4 ml ofnormal growth media, and incubated at 37°C. Endothelial cells expressed GFP thefollowing day. Down-regulation of Rictor and disruption of mTORC2 signaling wasassessed by using qRT-PCR and Western blotting. Steps that involved handling viruses orvirus-transfected cells were performed in a level-2 biosafety hood (Skan VSB 90) in acertified cell culture laboratory.
8.10. Endothelial network-formation assay in vitroAngiogenesis in vitro was assessed on the basis of a tube formation assay. Twenty-four-well culture plates (Costar; Corning) were coated with growth factor-reduced matrigel(BD Biosciences) in a total volume of 150μL and allowed to solidify for 30 min at 37°C.MAEC were trypsinized and re-suspended to a concentration of 10 5/mL in DMEM / 1%FCS. 500μl of the cell suspension were added into each well and complemented withdiluent (heparin) and growth factors (FGF2; VEGFA 25ng/ml with heparin). Then the cellswere incubated at 37°C for eighteen hours. The appearance of endothelial network wasobserved under an inverted microscope by fluorescence with a 4x objective (IX70,Olympus) and photographed. Number of master segments was quantified automaticallyusing the Macro ‘Angiogenesis Analyzer’ by Gilles Carpentier (Gilles Carpentiercontribution: Angiogenesis Analyzer, ImageJ News, 5 October 2012) for NIH Image J 1.47vProgram.
8.11. Fluorescent labeling of wild-type and Rictor KO cellsWild-type and Rictor KO MAEC were plated subconfluently (~10 6 cells) in a 15 cm cellculture dish and incubated overnight. For wild-type cells, tracking dye green (CytoPainter,abcam ab138891) was dissolved in 100 μl DMSO (=stock solution (1000x)). 20μl of stocksolution was mixed with 5 ml assay buffer. Cells were washed once with PBS, and 5 mltracking dye green working solution added to the cells and incubated for 45 min at 37 oC inan CO2 incubator. For KO cells, 10 μl of tracking dye Red DMSO stock solution (500X,Cytopainter, abcam ab138893) was mixed with 50μl of assay buffer for the workingsolution. Cells were washed once with PBS, 6 ml of growth medium and 60 μl of theworking solution added to the cells and incubated for 45 min at 37 oC in a CO2 incubator.
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Then, wild-type and KO cells were washed three times with PBS and 20 ml of growthmedium added to the culture. After 2 hours, efficacy of fluorescent labeling was assessedusing an Olympus IX71 microscope using Fluorescein isothiocyanate (FITC) (Ex/Em =490/520 nm) and Texas Red filter sets (Ex/Em = 570/600 nm) and cells werephotographed.
8.12. RNA extraction and real-time PCRqRT-PCR was performed as described previously 429, 445. RNA was isolated using RNAeasyMini kit (Qiagen, Hilden, #74106), followed by a on column DNA digestion (Qiagen, Hilden,Germany). cDNA was transcribed from total RNA using iScript™ Reverse TranscriptionSupermix for RT-qPCR (BIO-RAD, #170-8841). To control for DNA contamination in theqRT-PCR, for each sample a control reaction missing reverse transcriptase wasadditionally amplified.Primers used are listed in the Table 2. Primers were tested by cDNA dilution series toobtain optimal reaction conditions. qRT-PCR was performed using an iCycler iQ Real TimePCR Detection System (Biorad, Reinach, Switzerland) and iQ™ SYBR® Green Supermix(Biorad, #170-8882). Melting curve of each representative reaction was analyzed. TheqRT-PCR was quantified using the formula:  2-ΔCT where ΔCT = CT Tubulin – CT gene ofinterest443.
Table 2. Primers list
Gene Primer Forward (5’→3’) Primer Reverse (5’→3’)
Adamts1 GTG CCA GCT TGA ATG GTG TG ACG TGA CCA TGT AGG CAC TG
Ang2 TTA GCA CAA AGG ATT CGG ACA AT TTT TGT GGG TAG TAC TGT CCA TTC A
β-Tubulin TCA CTG TGC CTG AAC TTA CC GGA ACA TAG CCG TAA ACT GC
CalM3 GCT TTG AGA CTC TCC ACC CC CCT TGC CCT CAA CTC TAG GC
Casp8 v.1 AAC ATT CGG AGG CAT TTC TGT C AGA AGA GCT GTA ACC TGT GGC
Cd31 ACG AGA GCC ACA GAG ACG GTG T CGG GAC ATG GAC GAC CTC CCA
Cd34 GAG CCC TAC AGG AGA AAG GC ACT GTG AGG AGA GCA CAA AGG
Cre CGT ACT GAC GGT GGG AGA AT CCC GGC AAA ACA GGT AGT TA
Dvl3 v.x5 TGG ATG TGA TGT GAT CAG GGC GGT TAG GGG CTG TAG CAT GG
Emp1 v.1 CGC AAA TGC ATC TGT AGG GC GAG CTG GAA CAC GAA GAC CA
Fgfr1 CGT AGG CCT GTA GCT CCC TA TGA ACT TCA CCG TCT TGG CA
Flt3L v.1 GCT TCT GGA GGA CGT CAA CA TCC CGA TAC AGG GCT TCA GA
Gjα1 TAC CCA ACA GCA GCA GAC TTT GCC AAA GTG GTG GAA CTC CT
Hgf v.4 ACC CTG GTG TTT CAC AAG CA TCT ACA CGT CGG GGT AGC A
Icam-1 GAC GCA GAG GAC CTT AAC AG GAC GCC GCT CAG AAG AAC
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Id2 GGA CTC GCA TCC CAC TAT CG GAT GCC TGC AAG GAC AGG AT
Igfbp3 GTG ACC CGG ACA TCT GGA AG AGT AGA TCA GGC CAC TTG CG
Jagged1 AGA AGT CAG AGT TCA GAG GCG TCC AGT AGA AGG CTG TCA CCA AGC AAC
Klhl20 TGG ACA GCT TAT GGC AGT GG GCC GAC GGT AAT TCA TCC CT
Mcp1 CAG GTC CCT GTC ATG CTT CT GTG GGG CGT TAA CTG CAT CT
Notch2 GTT GAT CCC CGT CAG TGT GT CAG GAG GCT GAA GTC GGT TT
Notch3 GGC TTT GAG GGC ACT TTG TG CTC ACA GCG TAT GCC CGT AT
Opn v.4 CTG GCA GCT CAG AGG AGA AG ATT CTG TGG CGC AAG GAG AT
Pkcα GGA ATG AGT CCT TCA CGT TCA AA TTA GCT CTG AGA CAC CAA AGG
Pkp4 v.x3 CTC CGC CTG AGC TGG AAA G CAG TGG AGA CAG CTT CCT GG
Plcγ1 CCT GAG GGC AAA AAC AAC CG CTC CTG TGA GTC AGC TGC AA
Pten GCA GGA TAC GCG CTT GGG CAG CGG CTC AAC TCT CAA AC
Rictor ex.4-5 TGC GAT ATT GGC CAT AGT GA ACC CGG CTG CTC TTA CTT CT
SerpinE1 CCG ATG GGC TCG AGT ATG AC TTC TCA AAG GGT GCA GCG AT
Sm22α GCG GCC TTT AAA CCC CTC ACC C GAG GCA GAG AAG GCT TGG TCG T
sVegfr1 CTC CTC TGT CCA CCC AGG TA CTG CAC TTT TGC CGT CAG TC
Thbs1 v.x1 CAT GCC ATG GCC AAC AAA CA TTG CAC TCA CAG CGG TAC AT
Tsc1 v.1 TGG TAC CAC TGC AGG TGG AAA AG TGC ACA CAG TCA TCT TGG GG
tVegfr1 GTG TCT ATA GGT GCC GAG CC GTT CCT TGC ACG GTG AGG TA
Vcam-1 GGC TGC GAG TCA CCA TTG GCA CAG GTA AGA GTG TTC ATT C
VE-Cad GCT GAC CAG CCT CCA ACG GG TGC TCT CAA GTG AAA CCG GGC T
Vegfa TTC GTC CAA CTT CTG GGC TC CGA GCT AGC ACT TCT CCC AG
Vegfr2 GGA AGG CCC ATT GAG TCC AA GTT GGT GAG GAT GAC CGT GT
8.13. Protein extraction and immunoblottingTo extract proteins, cells were washed twice with ice cold PBS and then collected byscraping (BD Falcon, #353089) in cold RIPA buffer constituted by bidistilled H 2O, 50 mMTrisHCl (Fluka, #93363), 150 mM NaCl (Fluka, #71378), 1 mM EDTA (Sigma, #E-5134),1% Triton® X-100 (Fluka, #93418), 0.1% SDS (MERCK, #1.13760.0100) , 0.25% SodiumDeoxycholate (Sigma, # D6750) and containing a complete mini protease inhibitor (Roche,#11836153001) and a phosphatase inhibitor cocktail 2 (Sigma, #P5726) . The cellsuspension was then centrifuged for 15 minutes at 14,000 rpm at 4°C and the resultingsupernatant was stored in -80°C.The protein concentration measured by using a BCA protein assay kit (Thermo scientific,#23223). Equal amounts of protein were loaded onto an 8% acrylamide-SDS gel.Separated proteins were transferred to a nitrocellulose membrane (Whatman, #BA85)using a semidry blotting procedure, blocked for 1 hour at room temperature (RT) in 5%BSA (Sigma-Aldrich, #A7906) in Tris buffered saline complemented with 0.1% Tween
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(TBST). Membranes were washed once with TBST and incubated overnight at 4°C withone of the primary antibodies listed in the Table 3.The next day, the membrane was washed three times in TBST and incubated with asecondary antibody goat anti rabbit HRP 1:5,000 (Cell Signaling, #7074) or anti mouseHRP 1:50,000 (Cell Signaling, #7076) for 1 hour at room temperature. After another washstep, a chemiluminescent substrate that is used for the detection of HRP (ThermoScientific, #34080) was applied to the membrane, and then the membrane was incubatedfor 1 minute. The signal was detected with a CL-XPosure film (Thermo Scientific 34088),and the resulting bands were quantified by using ImageJ (Wayne Rasband, NIH, MD, USA).
Table 3. Antibodies list
mouse anti β-ACTIN Sigma #A-5441 1:10000
rabbit anti AKT Cell Signaling #9272 1:1000
rabbit anti CRE Recombinase Cell Signaling #7803 1:1000
rabbit anti MAPK  Cell Signaling #9102 1:1000
rabbit anti Phospho-AKT (Ser473)  Cell Signaling #9271 1:1000
rabbit anti Phospho-AKT (Thr308) Cell Signaling #9275 1:1000
rabbit anti Phospho-PKCα (Ser657) Santa Cruz Biotechnology #sc-12356 1:1000
rabbit anti Phospho-MAPK (Thr202/Tyr204) Cell Signaling #9101 1:1000
rabbit anti Phospho-S6K1(Thr 389) Cell Signaling #9205 1:1000
rabbit anti Phospho-S6 RP (Ser 235/236) Cell Signaling #4858 1:1000
rabbit anti PKCα Cell Signaling #2056S 1:1000
rabbit anti S6K1 Cell Signaling #9202 1:1000
rabbit anti RICTOR Cell Signaling #2140 1:1000
8.14. Proliferation assay4500 cells with 100 μl of growth media were seeded in a 96-well plate in 10 replicates.After serum-starvation (1% FCS) for 26 hours, cells were stimulated with 5-25 ng/ml ofFGF2 or VEGFA, 10% FCS or 100μg/ml of insulin. After 72 hours, 10 μl of WST-1 solution(Roche Molecular Diagnostics) was added for 2 hours. Absorption was measured (A 450nm-A690nm) by using a Spectramax M2 reader (Molecular Devices).
8.15. Migration assay (wound healing)MAECs were grown to confluence, starved (0.5% FCS) for 24 hours. A straight scratchusing a 200 µl sterile tip was applied to the confluent monolayer (Star Lab, #S1120-8810).
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The monolayer was stimulated with diluent, FGF2 (25 ng/ml). The migration of the cellswas photographed with an inverted microscope (Olympus IX71) at different time points(0, 1, 3, 6 and 9 hours after the stimulation) and measured with the software T-Scratch ®(Tobias Gebäck and Martin Schulz, ETH Zürich, 2008).
8.16. Mouse dorsal skin fold chamber and matrigel sealingTo study the capillary remodeling and angiogenesis in vivo we used the dorsal skin foldchamber as described previously 377 with a novel modification in order to deliver growthfactors via matrigel to the tissue. For chamber implantation, two symmetrical titaniumframes were mounted on the dorsal skin fold of the animal. One skin layer and theunderlying fat were then completely removed in a circular area of 15 mm in diameter, andthe remaining layers (consisting of striated skin muscle, subcutaneous tissue and skin)were covered with NaCl2 0.9% and a glass cover slip incorporated into one of the titaniumframes377. The animals were allowed to recover for two days. Skin was detached from theunderlying muscle and removed in a circular area of 7 mm in diameter from the back ofthe chamber. Growth-factor reduced matrigel was mixed with FGF2 (1.5 µg/ml) andHeparin (5 IU units) or Heparin alone. The defect on the back of the chamber was sealedwith 16 µl of the matrigel mixtures, allowed to polymerize, and covered with a glass coverslip.
8.17. Intravital microscopyRepetitive intravital microscopic analyses of skin microvasculature were carried out dailyover a time period of 7 days. Microscopic images were taken at 8 different areas within thecenter and the periphery of the wound. After injection of 0.2 ml FITC-labeled dextran (2%;MW 70000, Sigma-Aldrich, Munich, Germany) the microcirculation was visualized byintravital fluorescence microscopy (Leica DM/LM; Leica Microsystems, Wetzlar,Germany). Microscopic images were captured by a CCD television camera (KappaMesstechnik, Gleichen, Germany) and recorded on video (50Hz; Panasonic AG-7350-SVHS,Tokyo, Japan) for subsequent off-line analysis. Using × 10 (N-Plan ×10/0.25 LD, Leica),×20 (HCX Apo ×20/0.50W, Leica) objectives blood flow was monitored in capillaries of thesuperficial and deep dermal plexus of the skin muscle. The epi-illumination setup includeda mercury lamp with a blue filter (450–490nm/>520nm excitation/emission wavelength)and a green filter (530–560nm/>580nm).
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8.18. Matrigel plug assayThe matrigel plug assay was performed as previously described 446. In brief, 8-week-oldC57BL/6 mice were injected subcutaneously with 0.2 ml of matrigel containing 1.5 μg/mlbFGF with1 μl (5 IU) Heparin. The injected matrigel rapidly formed a single, solid gel plug.After 7 days, mice were euthanized, the skin was pulled back to expose the matrigel plug.The matrigel plug was removed, photographed and fixed in formalin and paraffinembedded. Hemoglobin content was estimated by measuring mean pixel densities fromfive random 200×200 pixel areas from the magenta channel in CMKY converted imagesfrom each plug by the NIH ImageJ program.The Matrigel plugs were removed and fixed in 4% buffered formalin. After 48 h fixation,the plugs were trimmed, dehydrated in graded alcohol and routinely paraffin waxembedded. Sections (3-5 µm thick) were prepared, mounted on glass slides, de-paraffinized in xylene, rehydrated through graded alcohols and stained with haematoxylinand eosin (HE) for the histological examination. For analysis of immunostainings, sectionsof one plug were photographed in three different areas (350 ×350 pixels), quantified andaveraged. The n number refers to the mean of 3 areas of one plug. E.g. for microvesselinvasion n=4/7 refers to 4 groups of  3 averaged areas from control plugs compared to 7groups of 3 averaged areas from 7 Rictor KO plugs. Immunohistology for CD31 antigenwas employed to highlight endothelial cells. Anti-CD-31 immunohistochemical stainingwas performed according to manufacturer’s protocol (Lifespan Biosciences). Slides werephotographed using a bright-field microscope (Zeiss Axioskop 2, Germany).Immunohistology for the CD68 antigen was employed to highlight cells of the monocyte /macrophage lineage447. Briefly, sections were de-paraffinized in xylene (2 × 5 min) andrehydrated in decreasing concentrations of ethanol (2 × 3 min washes in 100% ethanol,followed by 1 × 3 min wash in 96% ethanol). Sections were washed twice with Tris-buffered saline (TBS, 0.1 M Tris–HCl with 0.9% NaCl, pH 7.4) and incubated for 1 h at 37°Cwith the primary antisera (1:100, ab125212, Clone KP1, Abcam, Cambridge, UnitedKingdom), after heat pre-treatment in citrate acid (0.01M, pH 9.0) in a 97°C water bath for20 min. An anti-rabbit IgG DAB detection system was subsequently applied according tothe manufacturer’s protocols (Discovery OmniMap anti-Rb HRP, Roche, Basel,Switzerland). Sections were then washed 3 × in TBS and 1 × in distilled water andcounterstained for 1 min with haematoxylin, followed by rinsing for 5 min in tap waterand dehydration in ascending alcohols, clearing in xylene, coverslipping and mounting.Sections of murine immune system organs were used as positive control. All slides werescanned using digital slide scanner NanoZoomer-XR C12000 (Hamamatsu, Japan) andimages were taken using NDP.view2 viewing software (Hamamatsu).
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8.19. Whole mount cytoskeleton fluorescence stainingCells seeded in culture slides (Falcon, #354118) were starved overnight and consequentlystimulated with 25 ng/ml FGF2, 25 ng/ml VEGFA or full medium for 1, 3 and 6 hours. Inbrief, MAECs were fixed for 15 minutes with PBS containing 4% PFA and afterwardspermeabilized for 5 minutes with PBS containing 0.1% Triton ® X-100 (Fluka, #93418).Subsequently the samples were incubated for one hour at room temperature with AlexaFluor® 555 Phalloidin (Cell Signaling, #8953) diluted 1:20 in PBS and mounted in mediumcontaining DAPI (Life Technology, #P36935). The following day, images of the stainedcytoskeleton were taken using Zeiss micro-scope (SP5; Leica, Wetzlar, Germany).
8.20. Transcriptome analysisFull confluent MAEC monolayer was starved (0.5% serum) for 24 hours and consequentlystimulated with 25 ng/ml of FGF2 or VEGFA for either 3 or 24 hours. The RNA was thencollected, purified (RNA extraction chapter) and its integrity was checked on RNA NanoChips (Agilent Technologies, #5067-1511) with Agilent 2100 Bioanalyzer. Affymetrixwork flow was performed by the Functional Genomic Center Zürich. The Chip data weresubsequently validated with real-time PCR using the primers listed in Table 2.
8.21. Angiogenic ligandsA confluent MAECs monolayer starved with 0.5% serum for 24 hours was stimulated with25 ng/ml of FGF2 or VEGFA for 24 hours. After the incubation time, the cell supernatantand the cell lysates were collected. To collect the cell lysates, the cells were scraped inbuffer containing 1% Igepal CA-630 (Sigma, #I3021), 20 mM Tris-HCl (pH 8.0), 137 mMNaCl, 10% glycerol, 2 mM EDTA, 10 μg / mL Aprotinin (Sigma, #A6279), 10 μg / mLLeupeptin (Tocris, #1167), and 10 μg / mL Pepstatin (Tocris, #1190). Using the kitProteome Profiler (R&D Systems, #MVR100), the presence of proteins involved inangiogenesis was detected both in cell lysates and in the cell supernatants on CL-X Posurefilm (Thermo Scientific, #34090) and quantified with ImageJ software (Wayne Rasband,NIH, MD, USA). The transcription of angiogenesis ligands was also accessed on the RNAlevel after 1, 3, 6 and 24 hours of stimulation with FGF2 and VEGFA (primers listed inTable 2).
8.22. Nitrites quantificationMAECs were seeded confluent in a 6-well plate and starved in 1 ml of 0.5% FCS medium.The monolayer was then incubated for 20 minutes, 24 and 48 hours with different stimuli:
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FGF2 (25 ng/ml), VEGFA (25 ng/ml), full medium, ACh (10 µM) or TNFα (10 ng/ml). At theend of the incubation period, the supernatant was collected and the particles removedafter spinning. 100 µl of supernatant were put in duplicates in a 96-well plate and makereact first with 50 µl of 5% Ortho-phosphoric acid 1% sulfanilamide (Sigma, #S9251-100G) in water then with 50 µl of 0.1% N-(1-Naphthyl)ethylenediamine dihydrochloride(Sigma, #33461-5G) in water. The optical density of each duplicate, corresponding to theamount of nitrites in the supernatant, was measured at the spectrophotometer at 540 nmwave length.
8.23. Soluble VEGFR1 quantificationA starved (0.5% FCS) MAEC monolayer was incubated with 25 ng/ml of FGF2 or VEGFA at37°C for 24 hours. The supernatant of the cells was collected and the particulates removedby centrifugation. Using then the kit Quantikine ELISA (R&D Systems, #MVR100) theamount of soluble VEGFR1 was detected at the spectrophotometer (TECAN, Infinite#M200PRO).
8.24. Statistical analysisStatistical tests were performed by GraphPad Prism 5.04 software (San Diego, CA, USA).On a general basis, two-way analysis of variance (ANOVA), followed by a Bonferroni post-test comparing all pairings was calculated whereby a P value of less than 0.05 wasconsidered as statistically significant. For the comparison of two groups, the unpaired t-test was used.
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10.     ABBREVIATIONS
AArch = Aortic Arch
ACh = Acetylcholine
ADAMTS1 = A Disintegrin And Metalloproteinase with Thrombospondin Motifs 1
adipo = Adipocytes
AJ = Adherens Junctions
AKT = Protein kinase B
AMPK = AMP-activated protein Kinase
ANG = Angiopoietin
A-loop = Activation Loop
BSA = Albumin from Bovine Serum
C53BL/6 = C53 Black 6
CalM3 = Calmodulin 3
cAMP = Cyclic Adenosine Monophosphate
CASP8 v.1 = Caspase-8 (variant 1)
CD = Cluster of Differentiation
CD31 = see PECAM1
CD34 = Hematopoietic Progenitor Cell Antigen
cDNA = Complementary DNA
cm = Centimeter
COX = Cyclooxygenase
Ctrl = Control
DA = Dorsal Aorta
DAG = Diacyl-glycerol
DLAV = Dorsal Longitudinal Anastomotic Vessel
DLL4 = Delta Like Ligand 4
DMEM = Dulbecco’s Minimal Essential Medium
DNA = Deoxyribonucleic Acid
Dvl3 v.x5 = Segment polarity protein Dishevelled homolog DVL-3 (variant X5)
EC = Endothelial Cell
ECGS = Endothelial Cell Growth Supplement
EDTA = Ethylenediaminetetraacetic Acid
eIFs = Eukaryotic Initiation Factors
Emp1 = Epithelial Membrane Protein 1
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eNOS = Endothelial NOS
Eph = Ephrin
EPO = Erythropoietin
FCS = Fetal Calf Serum
FGF = Fibroblast Growth Factor
FGFR = FGF2 Receptor
Flt3L = FMS-Like Tyrosine kinase 3 Ligand
FoxOs  = Forkhead box protein O
GF = Growth Factor
GFP = Green Fluorescent Protein
Gjα1 = Gap Junction Alpha-1 protein
GSK3 = Glycogen Synthase Kinase 3
HCl = Hydrochloric Acid
HGF = Hepatocyte Growth Factor
HGF v4 = Hepatocyte Growth Factor (variant 4)
HIF = Hypoxia Inducible Factor
HM = Hydrophobic Motif
Hsp = Heat Shock Protein
HSPGs = Heparan Sulfates Proteoglycans
ICAM-1 = Intercellular Adhesion Molecule 1
ID2 = DNA-binding protein inhibitor
IGF = Insulin- like Growth Factor
IGFBP3 = Insulin-like Growth Factor-Binding Protein 3
IL = Interleukin
iNOS = Inducible NOS
IP3 = Inositol 1,4,5-Trisphosphate
ISV = Intersegmental Vessel
Jag1 = Jagged1
Klhl20 = Kelch-like protein 20
KO = Knock Out
MAEC = Mouse Aortic Endothelial Cell
MAPK = Mitogen-Activated Protein Kinase
MCP1 = Monocyte Chemotactic Protein 1
mM = Millimolar
MMPs = Matrix Metalloproteases
mTOR = Mammalian Target Of Rapamycin
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mTORC = Mammalian Target Of Rapamycin Complex
NaCl = Sodium Chloride
NADP (+/H) = Nicotinamide Adenine Dinucleotide Phosphate
NaPyr = Sodium Pyruvate
NEAA = Non Essential Amino Acid
NG2 = Neuron Glial 2
nm = Nanometer
nM =Nanomolar
nNOS = Neuronal NOS
NO = Nitric Oxide
NOS = Nitric Oxide Synthase
Notch = Neurogenic locus notch homolog protein
Nrp-1 = Neuropilin-1
NSAID = Non-Steroidal Anti-Inflammatory Drug
OD = Optical Density
OPN v.4 = Osteopontin (variant 4)
PCR = Polymerase Chain Reaction
PBS = Phosphate Buffer Solution
PDGF = Platelet Derived Growth Factor
PDK1 = Pyruvate Dehydrogenase lipoamide Kinase isozyme 1
PDT = Photodynamic Therapy
PECAM-1 = Platelet Endothelial Cell Adhesion Molecule 1
PenStrep = Penicillin Streptomycin
PFA = Paraformaldehyde
PHD = Prolyl Hydroxylase
PlGF = Placental Growth Factor
PIP3 = Phosphatidylinositol (3,4,5)-trisphosphate
PI3K = Phosphoinositide 3-kinase
PKCα = Protein Kinase C Alpha
Pkp4 = Plakophilin-4
PLCγ = Phosphoinositide Phospholipase Cγ
PMA = Phorbol-12-myristat-13-acetat
Pten = Phosphatase and tensin homolog
PVC = Posterior Cardinal Vein
RA = Rheumatoid Arthritis
RNA = Ribonucleic Acid
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RPE = Retinal Pigment Epithelium
RPM = Revolutions Per Minute
qRT-PCR = Quantitative Real Time PCR
SDS = Sodium Dodecyl Sulfate
Ser = Serine
SF = Scatter Factor, see also HGF
SGK1 = Serum and Glucocorticoid-regulated Kinase 1
SMA = Smooth Muscle Actin
SMC = Smooth Muscle Cell
S6K1 = Ribosomal protein S6 kinase beta-1
sVEGFR1 = Soluble Vascular Endothelial Growth Factor 1
TAM = Tumor Associated Macrophage
TBST = Tris Buffer Solution 0.1% Tween
TEM = Tie2- Expressing Monocytes
TF = Tissue Factor
TGF = Transforming Growth Factor
Thbs1 = Thrombospondin 1
Thr  = Threonine
TIE1 = Tyrosine kinase with immunoglobulin-like and EGF-like domains 1
TIE2 = Angiopoietin-1 receptor
TJ = Tight Junctions
TM  = Turn Motif
TNFα = Tumor Necrosis Factor Alpha
Tris = tris(hydroxymethyl)aminomethane
TSC (1/2) = Tuberous Sclerosis Complex (1 or 2)
TSPs = Thrombospondins
tVEGFR1 = Total Vascular Endothelial Growth Factor Receptor 1
Tyr  = Tyrosine
vBM = Vascular Basement Membrane
VCAM-1 = Vascular Cell Adhesion Molecule 1
VE-Cad = Vascular Endothelial Cadherin
VEGFA = Vascular Endothelial Growth Factor A
VEGFR1 = Vascular Endothelial Growth Factor Receptor 1
VEGFR2 = Vascular Endothelial Growth Factor Receptor 2
VEGFR3 = Vascular Endothelial Growth Factor Receptor 3
VHL = von Hippel-Lindau protein
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VPF = Vascular Permeability Factor, see also VEGF
vSMCs = Vascular Smooth Muscle Cells
vWF = von Willebrand Factor
wARMD = Wet Age- Related Macular Degeneration
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